Rec'd PCT/PTO 03 DEC 1999

FORM PTO-1390 (REV 5-93)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NO. P564-9049
	TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371	DATE: December 3, 1999
		U.S. APPLN. NO. (IF KNOWN, SEE 37 CFR 1.5) 09/424840

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP98/03397	5 June 1998	6/6/97; 12/12/97; 8/3/98

TITLE OF INVENTION: ANTI-GPIIB/IIIA RECOMBINANT ANTIBODIES

APPLICANT(S) FOR DO/EO/US: Peter BERCHTOLD, Robert F. A. ESCHER

1. XX This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
   (THE BASIC FILING FEE IS ATTACHED)

2. _ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.

3. XX This express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT articles 22 and 39(1).

4. XX A proper demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.

5. XX A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. XX is transmitted herewith (required only if not transmitted by the International Bureau).
   b. XX has been transmitted by the International Bureau.
   c. _ is not required, as the application was filed in the United States Receiving Office (RO/US)

6. XX A translation of the International Application into English (35 U.S.C. 371(c)(2)).

7. _ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. _ are transmitted herewith (required only if not transmitted by the International Bureau).
   b. _ have been transmitted by the International Bureau.
   c. _ have not been made; however, the time limit for making such amendments has NOT expired.
   d. _ have not been made and will not be made.

8. _ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).

9. XX An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).

10. XX A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. XX An Information Disclosure Statement under 37 CFR 1.97 and 1.98.

12. XX An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.

13. _ A FIRST preliminary amendment.
    _ A SECOND or SUBSEQUENT preliminary amendment.

14. _ A substitute specification.

15. _ A change of power of attorney and/or address letter.

16. XX Other items or information: PCT/RO/101, PCT/ISA/210, PCT/IPEA/416, PCT/IPEA/409, PCT/IPEA/409, Letter of Explanation Re Declaration

CHECK NO. 21589
Drawings - 7 sheets

U.S. APPLN. NO. (IF KNOWN, SEE 37 C.F.R. 1.50) 09/424840	INTERNATIONAL APPLICATION NO. PCT/EP98/03397	ATTORNEY DOCKET NO. P564-9049 DATE: December 3, 1999

17. XX The following fees are submitted: **Basic National Fee (37 CFR 1.492(a)(1)-(5):** Search Report has been prepared by the EPO or JPO.....$840.00 International preliminary examination fee paid to USPTO (37 CFR 1.482)..$670.00 No international preliminary examination fee paid to USPTO (37 CFR1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))..... $760.00 Neither international preliminary examination fee (37 CFR 1.482) or international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....$970.00 ~~International preliminary examination fee paid to USPTO (37 CFR 1.482) and all~~ claims satisfied provisions of PCT Article 33(2)-(4) .....$ 96.00	CALCULATIONS	PTO USE ONLY
ENTER APPROPRIATE BASIC FEE AMOUNT =	$840	
Surcharge of $130.00 for furnishing the oath or declaration later than _ 20 _ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	$00	

Claims	Number Filed	Number Extra	Rate		
Total Claims	28 - 20 =	08	X $ 18.00	$144	
Independent Claims	06 - 3 =	03	X $ 78.00	$234	
Multiple dependent claim(s) (if applicable)			+ $260.00	$260	
TOTAL OF ABOVE CALCULATIONS =				$1,218	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				$609	
SUBTOTAL =				$609	
Processing fee of $130.00 for furnishing the English translation later the _ 20 _ 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +				$00	
TOTAL NATIONAL FEE =				$609	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). $40.00 per property +				$40	
TOTAL FEES ENCLOSED =				$649	
				Amount to be refunded	$
				Charged	$

a. XX A check in the amount of $649 to cover the above fees is enclosed.
b. _ Please charge my Deposit Account No. 14-1060 in the amount of $_____ to cover the above fees. A duplicate copy of this sheet is enclosed.
c. XX The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1060.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

NIKAIDO, MARMELSTEIN, MURRAY AND ORAM LLP
Metropolitan Square
655 15th Street, N.W.
Suite 330 - G Street Lobby
Washington, D.C. 20005-5701
Telephone No. (202) 638-5000

Robert B. Murray
Reg. No. 22,980

Serial or Patent No.: _____ Docket No.: _____

Filed or Issued: _____

To: _____

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(c) - SMALL BUSINESS CONCERN

I hereby declare that I am

(X) the owner of the small business concern identified below:
( ) an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN ASAT AG Applied Science & Technology

ADDRESS OF CONCERN Baarerstraße 77, CH-6302 Zug, Switzerland

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled _____ by Inventor(s)

Peter Berchtold and Robert F. A. Escher described in

( ) the specification filed herewith
( ) application serial no. PCT/EP 98/03397 filed June 05, 1998
( ) patent no. _____, issued _____

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e). NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME _____

ADDRESS _____

( ) INDIVIDUAL (X) SMALL BUSINESS CONCERN ( ) NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28 (b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Dr. H.W. Schmid

TITLE OF PERSON OTHER THAN OWNER _____

ADDRESS OF PERSON SIGNING Riedmatt 5, Postfach 3542, 6302 Zug, Switzerland

SIGNATURE  DATE November 3, 1999

RECOMBINANT ANTI-GPIIB/IIIA ANTIBODIES

DESCRIPTION

The invention relates to novel nucleic acid sequences which encode human autoantibodies against blood platelet membrane proteins and which encode antiidiotypic antibodies, to novel amino acid sequences of human antibodies, and to their use for the diagnosis and therapy of diseases.

Autoimmune thrombocytopenic purpura (AITP) is an immune disease which is defined by a low blood platelet count associated with normal or elevated megakaryocytopoiesis. The destruction of platelets in the reticuloendothelial system (spleen, liver and bone marrow) is increased due to the presence of antiplatelet autoantibodies. These autoantibodies, which can be detected in about 75% of AITP patients, are predominantly directed against the platelet membrane glycoproteins (GP) IIb/IIIa and Ib/IX. Several different autoantibody specificities may be found in one and the same patient (cf., e.g., Berchtold and Wenger, Blood 81 (1993), 1246-1250; Kiefel et al., Br. J. Haematol. 79 (1991), 256-262; McMillan et al., Blood 70 (1987), 1040 and Fujisawa et al., Blood 79 (1991); 1441). However, it is still difficult to characterize binding epitopes and to ascertain the pathogenic significance of the autoantibodies due to the limited quantity of autoantibodies which can be obtained from AITP patients. It has only been possible to obtain a few human monoclonal antibodies from lymphocytes of AITP patients which react with GPIIb/IIIa AIPT using the hybridoma technique (Kunicki et al., Hum. Antibodies Hybridiomas 1 (1990) 83-95).

Natural autoantibodies against various selfantigens, for example against intracellular and cytoskeletal

components of human platelets, have also been reported to occur in healthy individuals (Guilbert et al., J. Immunol. 128 (1982), 2779-2787; Hurez et al., Eur. J. Immunol. 23 (1993), 783-789 and Pfueller et al., Clin. Exp. Immunol. 79 (1990), 367-373). Some of these autoantibodies which have been observed in sera from healthy individuals can also be directed against platelet-membrane proteins (Souberbielle, Eur. J. Haematol. 56 (1996), 178-180). However, the role of these natural autoantibodies, and there relationship to disease-associated autoantibodies, is still unknown.

Corticosteroids can be used for treating AITP. About half of the patients react within 4 weeks to an administration of prednisone; however long-term remissions are only rarely seen. The administration of high doses of intravenous immunoglobulin (IVIgG) is recommended as an emergency treatment for patients who are exhibiting severe bleeding or extremely low platelet counts. This treatment is followed in most patients by a rapid, but usually only transient, increase in the platelet count. The mechanisms by which corticosteroids and IVIgG act in the treatment of AITP are still unknown. Investigations carried out by Berchtold et al., (Blood 74 (1989), 2414-2417 and Berchtold and Wenger, Blood 81 (1993), 1246-1250) have disclosed that antiiodiotypic antibodies which are present in IVIgG can inhibit the binding of autoantibodies to platelet glycoproteins.

The problem underlying the present application is that of identifying novel DNA sequences which are responsible for autoantibodies binding to GPIIb/IIIa. This approach can be used for making available novel pharmaceutical preparations which can be employed for improving the diagnosis and therapy of AITP.

It was surprisingly possible to identify binding sequences from autoantibodies after using peripheral circulating B cells from a healthy human donor to prepare a combinatorial phagemid display library of human antibody heavy and light chains. Following the presentation of human heavy and light antibody Fab fragments on the surface of the filamentous phage M13, it was possible to identify phage clones which exhibit specific binding to GPIIb/IIIa.

For this, the phagemid library was brought consecutively into contact with thrombasthenic platelets lacking GPIIb/IIIa (negative selection) and normal platelets (positive selection). After several rounds of selection and amplification by infecting E.coli, 23 clones were obtained which were able to bind to the GPIIb/IIIa complex. Inhibition studies using pools of monoclonal antibodies directed against the GPIIb/IIIa yielded two groups of clones: both groups were inhibited by monoclonal antibodies which were specific for the GPIIb/IIIa complex and one group was also inhibited by a GPIIb-specific monoclonal antibody. These findings were confirmed by carrying out a DNA analysis of the clones which indicated the presence of 2 different anti-GPIIb/IIIa phage clones. These results demonstrate that 2 GPIIb/IIIa-specific phage clones, i.e. autoantibodies, can be cloned from the genome of a healthy individual and that these clones are able to recognize confirmational epitopes belonging to the GPIIb/IIIa complex. Inhibition studies furthermore established that both phage clones inhibit the binding of platelet-associated autoantibodies from AITP patients to purified GPIIb/IIIa and therefore presumably recognize GPIIb/IIIa epitopes which are AITP-associated. Since the phage clones contain the antigen-binding sequences of natural autoantibodies which are derived from the genome of a healthy individual, this finding can lead to new insights into

the origin of platelet-associated autoantibodies in AITP.

In addition to this, it is possible to use the novel phage clones to produce recombinant antiidiotypic antibodies against anti-GPIIb/IIIa autoantibodies, with the anti-GPIIb/IIIa phage clones being used as antigen. The recombinant antiidiotypic antibodies which can be obtained in this way constitute an attractive clinical alternative to using IVIgG.

The nucleotide sequences of the identified phage clones, and the amino acid sequences which are deduced from these nucleotide sequences, are depicted in the sequencing listings SEQ ID No. 1 to 8 (autoantibodies) and SEQ ID No. 9 to 18 (antiidiotypic antibodies).

I. Autoantibodies

A first aspect of the present invention relates to nucleic acids which encode auto-antibodies. Part of the subject-matter of the invention is therefore a nucleic acid which encodes the heavy chain of a human antibody, or a functional derivative or a fragment thereof, and encompasses a CDR3 region, selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:
V L P F D P I S M D V, (I)

(b) a nucleotide sequence which encodes the amino acid sequence:
A L G S W G G W D H Y M D V, (II)

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80%, and preferably at least 90%, with an amino acid sequence from (a) or (b), and

(d) a nucleotide sequence which encodes an amino acid sequence having an equivalent ability to bind to GPIIb/IIIa.

The novel nucleic acid furthermore preferably comprises a CDR1 region selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:
G Y S W R, (III)

(b) a nucleotide sequence which encodes the amino acid sequence:
S Y A M H, (IV)
and

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80%, and preferably at least 90%, with an amino acid sequence from (a) or (b).

The novel nucleic acid preferably furthermore comprises a CDR2 region selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:
D I S Y S G S T K Y K P S L R S, (V)

(b) a nucleotide sequence which encodes the amino acid sequence:
V I S Y D G S N K Y Y A D S V K G, (VI)
and

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80%, and preferably at least 90%, with an amino acid sequence from (a) or (b).

A second aspect of the present invention is a nucleic acid which encodes the light chain of a human antibody, or a functional derivative or a fragment thereof, and comprises a CDR3 region, selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:
A T W D D G L N G P V, (VII)

(b) a nucleotide sequence which encodes the amino acid sequence:

A A W D D S L N G W V, (VIII)

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80%, and preferably of at least 90%, with an amino acid sequence from (a) or (b), and

(d) a nucleotide sequence which encodes an amino acid sequence having an equivalent ability to bind to GPIIb/IIIa.

The novel nucleic acid preferably furthermore comprises a CDR1 region selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:
S G S S S N I R S N P V S, (IX)

(b) a nucleotide sequence which encodes the amino acid sequence:
S G S S S N I G S N T V N, (X)
and

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80%, and preferably at least 90%, with an amino acid sequence from (a) or (b).

In addition, the novel nucleic acid preferably further comprises a CDR2 region selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:
G S H Q R P S, (XI)

(b) a nucleotide sequence which encodes the amino acid sequence:
S N N Q R P S, (XII)
and

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80%, and preferably at least 90%, with an amino acid sequence from (a) or (b).

II. Antiidiotypic antibodies

A second aspect of the present invention relates to nucleic acids which encode antiidiotypic antibodies. Part of the subject-matter of the invention is therefore a nucleic acid which encodes the heavy chain of a human antibody, or a functional derivative or a fragment thereof, and comprises a CDR3 region, selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:
V R D L G Y R V L S T F T F D I, (XIII)

(b) a nucleotide sequence which encodes the amino acid sequence:
D G R S G S Y A R F D G M D V, (XIV)

(c) a nucleotide sequence which encodes the amino acid sequence:
M G S S V V A T Y N A F D I, (XV)

(d) a nucleotide sequence which encodes the amino acid sequence:
D A D G D G F S P Y Y F P Y, (XVI)

(e) a nucleotide sequence which encodes the amino acid sequence:
L R N D G W N D G F D I, (XVII)

(f) a nucleotide sequence which encodes the amino acid sequence:
D S E T A I A A A G R F D I, (XVIII)

(g) a nucleotide sequence which encodes the amino acid sequence:
E D G T T V P S Q P L E F, (XIX)

(h) a nucleotide sequence which encodes the amino acid sequence:
G S G S Y L G Y Y F D Y, (XX)

(i) a nucleotide sequence which encodes the amino acid sequence:
G L R S Y N Y G R N L D Y, (XXI)

(j) a nucleotide sequence which encodes an amino acid sequence having an homology of at least

80%, and preferably of at least 90%, with an amino acid sequence from (a), (b), (c) or (d), and

(k) a nucleotide sequence which encodes an amino acid sequence having an equivalent ability to bind to autoantibodies against GPIIb/IIIa.

The novel nucleic acid furthermore preferably comprises a CDR1 region selected from: a nucleotide sequence which encodes the amino acid sequences N F A M S, S Y T M H, D Y A L H or S H Y W S shown in Tab. 7a, a nucleotide sequence which encodes the amino acid sequence T Y Y W S, a nucleotide sequence which encodes the amino acid sequences D Y G M H, S H T I S, K Y A I H or E L S M H shown in Tab. 7b, and a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80%, and preferably at least 90%, with one of the previously mentioned amino acid sequences.

Preferably, the novel nucleic acid furthermore comprises a CDR2 region selected from a nucleotide sequence which encodes the amino acid sequences G I S G G G L L T H Y A (D/N) S V K G, L I S Y D G S N K Y Y A D S V K G, G I S W D S T S I G Y A D S V K G or F I Y D G A R T R F N P S L R S shown in Tab. 7a, a nucelotide sequence which encodes the amino acid sequence YIYYSGNTNYNPSLKS, a nucleotide sequence which encodes the amino acid sequences A I S Y D G S N K Y Y A D S V K G, G I T P I F G T V N Y A Q K F Q G, A I S S N G G N T Y Y A D S V K G or G F D P E D G E T I Y A Q K F Q G shown in Tab. 7b, and a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80%, and preferably of at least 90%, with one of the previously mentioned amino acid sequences.

Another part of the subject-matter of the present invention is a nucleic acid which encodes the light

chain of a human antibody, or a functional derivative or a fragment thereof, and comprises a CDR3 region, selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:

C S Y V H S S T N, (XXII)

(b) a nucleotide sequence which encodes the amino acid sequence:

Q V W D N T N D Q, (XXIII)

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80%, and preferably at least 90%, with an amino acid sequence from (a), and

(d) a nucleotide sequence which encodes an amino acid sequence having an equivalent ability to bind to autoantibodies against GPIIb/IIIa.

Preferably, the novel nucleic acid furthermore comprises a CDR1 region selected from a nucleotide sequence which encodes the amino acid sequence T G T S S A I G N Y N F V P shown in Tab. 7a, a nucleotide sequence which encodes the amino acid sequence G G Y K I G S K S V H shown in Tab. 7b, and a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80%, and preferably of at least 90%, with the previously mentioned amino acid sequence.

In addition, the novel nucleic acid preferably furthermore comprises a CDR2 region selected from a nucleotide sequence which encodes the amino acid sequence E G S K R P S shown in Tab. 7a, a nucleotide sequence which encodes the amino acid sequence E D S Y R P S shown in Tab. 7b, and a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80%, and preferably at least 90%, with the previously mentioned amino acid sequence.

Within the meaning of the present invention, the phrase "functional derivative of a chain of a human antibody" is to be understood as meaning a polypeptide which encompasses at least a CDR3 region of the heavy and/or light chain, as defined above, and which is able, where appropriate together with the relevant complementary chain of the human antibody (or a derivative of such a chain), to form an antibody derivative which possesses a recognition specificity for an antigen which is equivalent to that possessed by the non-derivatized antibody. Preferably, such an antibody derivative has a binding constant for the relevant antigen of at least 10^{-5} l/mol, preferably of at least 10^{-8} l/mol.

Functional derivatives of chains of a human antibody can be prepared, for example, by using recombinant DNA techniques to delete, substitute and/or insert segments of the gene encoding the relevant polypeptide.

Single-chain antibodies, which can, for example, be composed of the variable domains of the H and L chains or one or two H chain domains and, where appropriate a constant domain, are particularly preferred functional derivatives of antibody chains or antibodies. The preparation of such constructs is described in Hoogenboom et al., Immunol. Rev. 130 (1992), 41-68; Barbas III, Methods: Companion Methods Enzymol. 2 (1991), 119 and Plückthun, Immunochemistry (1994), Marcel Dekker Inc., Chapter 9, 210-235.

Within the meaning of the present invention, the phrase "equivalent ability to bind" is to be understood as being a binding affinity and/or specificity, i.e. epitope recognition, which is the same as that in the specifically disclosed sequences.

Another part of the subject-matter of the present invention is a vector which contains at least one copy

of a novel nucleic acid. This vector can be a prokaryotic vector or a eukaryotic vector. Plasmids, cosmids and bacteriophages are examples of prokaryotic vectors. Such vectors are, for example, described in detail in Chapters 1 to 4 in Sambrook et al., Molecular Cloning. A Laboratory Manual, 2nd edition (1989), Cold Spring Harbor Laboratory Press. A prokaryotic vector is preferably a plasmid or a phage.

On the other hand, the vector can also be a eukaryotic vector, e.g. a yeast vector, an insect vector (baculovirus) or a mammalian vector (plasmid vector or viral vector). Examples of eukaryotic vectors are described in Sambrook at al., loc. cit., Chapter 16, and Winnacker, Gene und Klone, Eine Einführung für die Gentechnologie [Genes and clones, an introduction to genetic engineering] (1985), VCH Verlagsgesellschaft, in particular Chapters 5, 8 and 10.

Yet another part of the subject-matter of the present invention is a cell which expresses a novel nucleic acid, or a cell which is transformed with a novel nucleic acid or with a novel vector. The cell can be a prokaryotic cell (e.g. a Gram-negative bacterial cell, in particular E.coli) or a eukaryotic cell (e.g. a yeast, plant or mammalian cell). Examples of suitable cells and methods for introducing the novel nucleic acid into such cells can be found in the above literature references.

Another part of the subject-matter of the present invention is a polypeptide which is encoded by a novel nucleic acid, in particular a recombinant polypeptide. Particularly preferably, the polypeptide contains the variable domain of the H chain and/or L chain of a human antibody.

Particular preference is given to a polypeptide which exhibits antibody properties and whose subunit components are a heavy chain, or a functional derivative thereof, and a light chain, or a functional derivative thereof. The polypeptide can be composed of two separate chains or be present as a single-chain polypeptide.

Yet another part of the subject-matter of the present invention is an antibody against a novel polypeptide, which antibody is directed against a region of the polypeptide which is responsible for recognizing the antigen. This antibody can be a polyclonal antiserum, a monoclonal antibody or a fragment of a polyclonal or monoclonal antibody (e.g. a Fab, $F(ab)_2$, Fab' or $F(ab')_2$ fragment). The antibody is preferably directed against the CDR3 region of the heavy and/or light antibody chain of the novel polypeptide, or a region thereof. Known methods can be used to obtain such antibodies by immunizing an experimental animal with a peptide or polypeptide which contains a novel CDR3 region and isolating the resulting polyclonal antibody from the experimental animal. In addition, monoclonal antibodies can be obtained by fusing an antibody-producing B cell from the experimental animal with a leukaemia cell in accordance with the method of Köhler and Milstein or a further development of this method. In addition, recombinant antibodies which are directed against the CDR3 region of the novel polypeptide can also be obtained by screening a suitable phagemid library, e.g. a phagemid library from a healthy human donor, with a novel polypeptide being used as the antigen.

The invention also relates to a pharmaceutical composition which comprises a nucleic acid, a vector, a polypeptide, an antibody or a cell as previously mentioned, as active component, where appropriate together with other active components and also

pharmaceutically customary adjuvants, additives or excipients.

The pharmaceutical composition can be used for preparing a diagnostic or therapeutic agent. Examples of diagnostic uses are the diagnosis of AITP or of a predisposition for AITP. Another preferred diagnostic use is that of monitoring the course of the AITP disease.

The use of the pharmaceutical composition as a diagnostic agent can comprise, for example, detecting a B cell subpopulation which is expressing a novel polypeptide as the antibody. This antibody can be detected, for example, at the nucleic acid level, e.g. by means of a nucleic-acid-hybridization assay, together with prior amplification where appropriate. On the other hand, the antibody can also be detected as to the protein level by means of an immunoassay using antigens or antibodies which react specifically with the polypeptide.

Furthermore, the novel pharmaceutical composition can also be applied in the therapeutic field, in particular for the prevention or therapy of AITP. This therapeutic use can, for example, be based on stimulating the production of anti-autoantibodies. For this, the novel autoantibody polypeptide can, for example, be administered to a patient, thereby eliciting and/or stimulating the formation of antiidiotypic antibodies. In this connection, this administration can be effected in accordance with customary immunization protocols (Fox et al., J. Pharmacol. Exp. Ther. 279 (1996), 1000-1008; Whittum-Hudson et al., Nat. Med. 2 (1996), 1116-1121; Jardieu, Curr. Opin. Immunol. 7 (1995), 779-782). On the other hand, the expression of antibody genes can be inhibited specifically by administering suitable antisense nucleic acids. The novel

antiidiotypic antibody polypeptide can be administered to a patient in order to achieve direct inhibition of the autoantibody activity.

Investigations carried out on the novel autoantibody polypeptides have shown that these polypeptides are surprisingly able to inhibit the binding of fibrinogen to blood platelets. The novel autoantibody polypeptides and antiidiotypic antibody polypeptides can therefore be employed, where appropriate in combination, as agents for modulating blood coagulation, in particular for preventing a thrombosis, for example following cardiac infarctions or strokes, or in association with venous thromboses together with lung embolisms or ischaemias, etc.

Murine monoclonal antibodies, e.g. the monoclonal antibody 7E3 (cf., e.g., US patent 5,440,020) or fragments thereof (e.g. the commercially available Fab fragment ReoPro®), or short synthetic peptides, have hitherto been used as fibrinogen antagonists for therapeutic purposes. However, murine monoclonal antibodies and antibody fragments suffer from the disadvantage that, as a result of their immunogenicity, they give rise to undesirable side reactions when used for treating human patients, while short peptides are generally degraded very rapidly. As compared with these known agents, the novel polypeptides have the advantage that they consist of amino acid sequences of human origin and therefore exhibit fewer undesirable side effects than do corresponding murine antibodies or antibody fragments, and that, because of their size, they are not subjected to such rapid degradation as are peptides.

The invention therefore relates to the use of a novel nucleic acid, in particular a nucleic acid which encodes an autoantibody polypeptide, of a vector which

contains this nucleic acid, of a cell which is transformed with the nucleic acid or the vector, of a polypeptide which is encoded by the nucleic acid, or of a pharmaceutical composition which comprises one or more of the said substances, for preparing an agent for affecting and in particular inhibiting the binding of fibrinogen to blood platelets. Preference is given to using the agent for modulating blood coagulation, in particular for dissolving thrombi and/or for preventing the formation of thrombi. The administration of the novel pharmaceutical composition can be effected in accordance with protocols which have already been established for murine antibodies or antibody fragments.

Yet another part of the subject-matter of the invention is a process for isolating phagemid clones which express nucleic acids which encode autoantibodies against GPIIb/IIIa or encode antiidiotypic antibodies which are directed against these autoantibodies. characterized in that a phagemid library is prepared from lymphocytes from a human donor and the desired phagemid clones are isolated by affinity selection, comprising negative and positive selection steps. Preferably, the process also involves isolating antibody-encoding nucleic acids from the clones and/or using the antibody-encoding nucleic acids for expressing recombinant antibody chains or derivatives or fragments thereof.

The invention is also explained by the following examples, figures and sequence listings, in which

SEQ ID No. 1 shows the nucleotide sequence of the H chain of a novel antibody (phagemid clone PDG7), with framework region (FR)1 extending from bp 1 to 90, complement-determining region (CDR)1 from bp 91 to

105, FR2 from bp 106 to 147, CDR2 from bp 148 to 195, FR3 from bp 196 to 291, CDR3 from bp 292 to 324 and FR4 from bp 325 to 357,

SEQ ID No.2 shows the amino acid sequence corresponding to the nucleotide sequence depicted in SEQ ID No.1, with FR1 extending from AA 1 to 30, CDR1 from AA 31 to 35, FR2 from AA 36 to 49, CDR2 from AA 50 to 65, FR3 from AA 66 to 97, CDR3 from AA 98 to 108 and FR4 from AA 109 to 119,

SEQ ID No.3 shows the nucleotide sequence of the L chain of a novel polypeptide (phagemid clone PDG7), with FR1 extending from bp 1 to 60, CDR1 from bp 61 to 99, FR2 from bp 100 to 144, CDR2 from bp 145 to 165, FR3 from bp 166 to 261, CDR3 from bp 262 to 294 and FR4 from bp 295 to 333,

SEQ ID No.4 shows the amino acid sequence corresponding to the nucleotide sequence given in SEQ ID No. 3, with FR1 extending from AA 1 to 20, CDR1 from AA 21 to 33, FR2 from AA 34 to 48, CDR2 from AA 49 to 55, FR3 from AA 56 to 87, CDR3 from AA 88 to 98 and FR4 from AA 99 to 11 [sic],

SEQ ID No.5 shows the nucleotide sequence of the H chain of a novel polypeptide (phagemid clone PDG13), with FR1 extending from bp 1 to 90, CDR1 from bp 91 to 109, FR2 from bp 106 to 147, CDR2 from bp 148 to 198, FR3 from bp 199 to 294, CDR3 from

bp 295 to 336 and FR4 from bp 337 to 369,

SEQ ID No.6 shows the amino sequence corresponding to the nucleotide sequence depicted in SEQ ID No.5, with FR1 extending from AA 1 to 30, CDR1 from AA 31 to 35, FR2 from AA 36 to 49, CD2 from AA 50 to 66, FR3 from AA 67 to 98, CDR3 from AA 99 to 112 and FR4 from AA 113 to 123,

SEQ ID No.7 shows the nucleotide sequence of the L chain of a novel polypeptide (phagemid clone PGD13), with FR1 extending from bp 1 to 60, CDR1 from bp 61 to 99, FR2 from bp 100 to 144, CDR2 from bp 145 to 165, FR3 from bp 166 to 261, CDR3 from bp 262 to 294 and FR4 from bp 295 to 333,

SEQ ID No.8 shows the amino acid sequence of the nucleotide sequence depicted in SEQ ID No. 7, with FR1 extending from AA 1 to 20, CDR1 from AA 21 to 33, FR2 from AA 34 to 48, CDR2 from AA 49 to 55, FR3 from AA 56 to 87, CDR3 from AA 88 to 98 and FR4 from AA 99 to 111,

SEQ ID No.9 shows the nucleotide sequence of the H chain of a novel polypeptide (phagemid clone AI-X16), with FR1 extending from bp 1 to 90, CDR1 from bp 91 to 105, FR2 from bp 106 to 147, CDR2 from bp 148 to 198, FR3 from bp 199 to 288, CDR3 from bp 289 to 336 and FR4 from bp 337 to 369,

SEQ ID No.10 shows the amino acid sequence of the nucleotide sequence depicted in SEQ ID No. 9, with FR1 extending from AA 1 to 30, CDR1 from AA 31 to 35, FR2 from AA 36 to 49, CDR2 from AA 50 to 66, FR3 from AA 67 to 96, CDR3 from AA 97 to 112 and FR4 from AA 113 to 123,

SEQ ID No. 11 shows the nucleotide sequence of the L chain of a novel polypeptide (phagemid clone AI-X16), with FR1 extending from bp 1 to 60, CDR1 from bp 61 to 102, FR2 from bp 103 to 147, CDR2 from bp 148 to 168, FR3 from bp 169 to 264, CDR3 from [lacuna] 265 to 291 and FR4 from bp 292 to 375,

SEQ ID No. 12 shows the amino acid sequence of the nucleotide sequence depicted in SEQ ID No. 11, with FR1 extending from AA 1 to 20, CDR1 from AA 21 to 34, FR2 from AA 35 to 49, CDR2 from AA 50 to 56, FR3 from AA 57 to 88, CDR3 from AA 89 to 97 and FR4 from AA 89 to 125,

SEQ ID No. 13 shows the nucleotide sequence of the H chain of a novel polypeptide (phagemid clone AI-X20), with FR1 extending from bp 1 to 90, CDR1 from bp 91 to 105, FR2 from bp 106 to 147, CDR2 from bp 148 to 195, FR3 from bp 196 to 291, CDR3 from bp 292 to 333 and FR4 from bp 334 to 366,

SEQ ID No. 14 shows the amino acid sequence of the nucleotide sequence depicted in SEQ ID No. 13, with FR1 extending from AA 1 to 30, CDR1 from AA 31 to 35, FR2 from AA

36 to 49, CDR2 from AA 50 to 65, FR3 from AA 66 to 97, CDR3 from AA 98 to 111 and FR4 from AA 112 to 122,

SEQ ID No. 15 shows the nucleotide sequence of the H chain of a novel polypeptide (phagemid clone AI-X39), with FR extending from bp 1 to 90, CDR1 from bp 91 to 105, FR2 from bp 106 to 147, CDR2 from pb [sic] 148 to 198, FR3 from bp 199 to 294, CDR3 from bp 295 to 339 and FR4 from 340 to 372,

SEQ ID No. 16 shows the amino acid sequence of the nucleotide sequence depicted in SEQ ID No. 15, with FR1 extending from AA 1 to 30, CDR1 from AA 31 to 35, FR2 from AA 36 to 49, CDR2 from AA 50 to 66, FR3 from AA 67 to 98, CDR3 from AA 99 to 113 and FR 4 from AA 114 to 124,

SEQ ID No. 17 shows the nucleotide sequence of the H chain of a novel polypeptide (phagemid clone AI-X40), with FR1 extending from bp 1 to 90, CDR1 from bp 91 to 105, FR2 from bp 106 to 147, CDR2 from bp 148 to 198, FR3 from bp 199 to 297, CDR3 from bp 298 to 339 and FR4 from bp 340 to 372,

SEQ ID No. 18 shows the amino acid sequence of the nucleotide sequence depicted in SEQ ID No. 17, with FR1 extending from AA 1 to 30, CDR1 from AA 31 to 35, FR2 from AA 36 to 49, CDR2 from AA 50 to 66, FR3 from AA 67 to 99, CDR3 from AA 100 to 113 and FR4 from AA 114 to 124,

SEQ ID No. 19 shows the nucleotide sequence of the H chain of a novel polypeptide (phagemid clone AI-X2), with FR1 extending from bp 1 to 90, CDR1 from bp 91 to 105, FR2 from bp 106 to 147, CDR2 from bp 148 to 195, FR3 from bp 196 to 291, CDR3 from bp 292 to 327 and FR4 from bp 328 to 360,

SEQ ID No. 20 shows the amino acid sequence of the nucleotide sequence depicted in SEQ ID No. 19, with FR1 extending from AA 1 to 30, CDR1 from AA 31 to 35, FR2 from AA 36 to 49, CDR2 from AA 50 to 65, FR3 from AA 66 to 97, CDR3 from AA 98 to 109 and FR4 from AA 110 to 120,

SEQ ID No. 21 shows the nucleotide sequence of the H chain of a novel polypeptide (phagemid clone AI-B14), with FR1 extending from bp 1 to 90, CDR1 from bp 91 to 105, FR2 from bp 106 to 147, CDR2 from bp 148 to 198, FR3 from bp 199 to 294, CDR3 from bp 295 to 336 and FR4 from bp 337 to 369;

The following variations in the sequence were also found: a C can be present at position 7, while a G can be present at position 9, a G at position 13, a G at position 15, an A at position 91, a G at position 92, a C at position 98, a T at position 149, an A at position 205, an A at position 228, an A at position 251, a T at position 253 and/or an A at position 284. The consequence of this is that, in the amino acid sequence (cf. SEQ ID No. 22), a Q can be present at

position 3, while a V can be present at position 5, an S at position 31, an A at position 33, a V at position 50, a T at position 69, a K at position 76, an N at position 84, an S at position 85 and/or a Y at position 95.

SEQ ID No. 22 shows the amino acid sequence of the nucleotide sequence depicted in SEQ ID No. 21, with FR1 extending from AA 1 to 30, CDR1 from AA 31 to 35, FR2 from AA 36 to 49, CDR2 from AA 50 to 66, FR3 from AA 67 to 98, CDR3 from AA 99 to 112 and FR4 from AA 113 to 123,

SEQ ID No. 23 shows the nucleotide sequence of the H chain of a novel polypeptide (phagemid clone AI-B18), with FR1 extending from bp 1 to 90, CDR1 from bp 91 to 105, FR2 from bp 106 to 147, CDR2 from bp 148 to 198, FR3 from bp 199 to 294, CDR3 from bp 295 to 333 and FR4 from bp 334 to 366;

The following variations in the nucleotide sequence were also found: thus, a C can be present at position 7, while a G can be present at position 13, a C at position 16, an A at position 56, a T at position 94, a G at position 97, a T at position 155, a C at position 173, a T at position 223, a T or a C at position 252, a G at position 261, a G at position 267, an A at position 271, a C at position 275 and/or a G at position 277. The consequence of this is that, in the corresponding amino acid sequence (cf. SEQ ID No. 24), a Q can be present

at position 3, while a V can be present at position 5, a Q at position 6, a K at position 19, a Y at position 32, an A at position 33, an I at position 52, an A at position 58, an S at position 75, an S at position 84, an R at position 87, an E at position 89, a T at position 91, an A at position 92 and/or a V at position 93.

SEQ ID No. 24 shows the amino acid sequence of the nucleotide sequence depicted in SEQ ID No. 23, with FR1 extending from AA 1 to 30, CDR1 from AA 31 to 35, FR2 from AA 36 to 49, CDR2 from AA 50 to 66, FR3 from AA 67 to 98, CDR2 from AA 99 to 111 and FR4 from AA 112 to 122,

SEQ ID No. 25 shows the nucleotide sequence of the H chain of a novel polypeptide (phagemid clone AI-B24), with FR1 extending from bp 1 to 90, CDR1 from bp 91 to 105, FR2 from bp 106 to 147, CDR2 from bp 148 to 198, FR3 from bp 199 to 294, CDR3 from bp 295 to 330 and FR4 from bp 331 to 363;

The following variations in the nucleotide sequence were also found: a C can be present at position 7, while a G can be present at position 9, a G at position 13, a G at position 15, a G at position 31, an A at position 46, a G at position 67, a G at position 89, a G at position 92, a C at position 93, a G at position 98, a G at position 102, a G at position 140, a G at position 141, a G at position 145, a T at position 149, a

T at position 157, an A at position 158, a G at position 160, an A at position 166, an A at position 173, a T at position 235, an A at position 251, a C at position 290 and/or an A at position 293. The consequence of this is that, in the corresponding amino acid sequence (cf. SEQ ID No. 26), a Q can be present at position 3, while a V can be present at position 5, a V at position 11, an R at position 16, an A at position 23, an S at position 30, an S at position 31, a G at position 33, an M at position 34, a W at position 47, an A at position 49, a V at position 50, a Y at position 53, a D at position 54, an S at position 56, a K at position 58, an L at position 79, an N at position 84, an A at position 97 and/or a K at position 98.

SEQ ID No. 26 shows the amino acid sequence of the nucleotide sequence depicted in SEQ ID No. 25, with FR1 extending from AA 1 to 30, CDR1 from AA 31 to 35, FR2 from AA 36 to 49, CDR2 from AA 50 to 66, FR3 from AA 67 to 98, CDR3 from AA 99 to 110 and FR4 from AA 111 to 121,

SEQ ID No. 27 shows the nucleotide sequence of the L chain of a novel polypeptide (phagemid clone AI-B24), with FR1 extending from bp 1 to 60, CDR1 from bp 61 to 96, FR2 from bp 97 to 138, CDR2 from bp 139 to 159, FR3 from bp 160 to 255, CDR3 from bp 256 to 282 and FR4 from bp 283 to 366;

The following variations in the nucleotide sequence were also found: a C or a T can be present at position 4, while a G can be present at position 37, an A at position 40, a G at position 50, an A at position 67, a T at position 72, an A at position 133, a T at position 136, a T or a C at position 138, a G at position 148, a T at position 160, a T at position 161, a T or a C at position 162, a C at position 200, a T at position 217, a G at position 218, an A or a C at position 220, a G at position 269, a T at position 271, a G at position 272, a G at position 275 and/or a T or a C at position 282. The consequence of this is that, in the corresponding amino acid sequence (cf. SEQ ID No. 28), an L can be present at position 2, while a G can be present at position 13, a K at position 14, an R at position 17, an N at position 23, an N at position 24, an I at position 45, a Y at position 47, a D at position 50, an F at position 54, a T at position 67, an S at position 73, an R at position 74, an S at position 90, an S at position 91, an S at position 92 and/or an H at position 94.

SEQ ID No. 28 shows the amino acid sequence of the nucleotide sequence depicted in SEQ ID No. 27, with FR1 extending from AA 1 to 20, CDR1 from AA 21 to 32, FR2 from AA 33 to 46, CDR2 from AA 47 to 53, FR3 from AA 54 to 85, CDR3 from AA 86 to 94 and FR4 from AA 95 to 122,

SEQ ID No. 29 shows the nucleotide sequence of the H chain of a novel polypeptide (phagemid clone AI-B38), with FR1 extending from bp 1 to 90, CDR1 from bp 91 to 105, FR2 from bp 106 to 147, CDR2 from bp 148 to 198, FR3 from bp 199 to 294, CDR3 from bp 295 to 333 and FR4 from bp 334 to 366;

The following variations in the nucleotide sequence were also found: a C can be present at position 7, while a G can be present at position 9, a G at position 13, an A at position 15 and/or a C at position 16. The consequence of this is that, in the corresponding amino acid sequence, a Q can be present at position 3, while a V can be present at position 5 and/or a Q can be present at position 6, and

SEQ ID No. 30 shows the amino acid sequence of the nucleotide sequence depicted in SEQ ID No. 29, with FR1 extending from AA 1 to 30, CDR1 from AA 31 to 35, FR2 from AA 36 to 49, CDR2 from AA 50 to 66, FR3 from AA 67 to 98, CDR3 from AA 99 to 111 and FR4 from AA 112 to 122.

Figure 1 shows the inhibition of the binding of autoantibody phabs (PDG-X) to GPIIb/IIIa which is brought about by adding the antiidiotypic antibody phab AI-X17.

Figure 2 shows the inhibition of the binding of autoantibody phabs (PDG-B) to blood platelets which is brought about by antiidiotypic antibody phabs AI-B,

Figure 3 shows the binding of autoantibody phabs to untreated and EDTA-treated blood platelets,

Figure 4 shows the inhibition of the binding of fibrinogen to GPIIb/IIIa which is brought about by autoantibody phabs,

Figures 5-7 show the inhibition of the binding of autoantibody phabs to GPIIb/IIIa which is brought about by the antibody 7E3 and the antibody fragment ReoPro®.

Examples

1. Identification of autoantibody sequences

1.1. Isolation of autoantibodies

Autoantibodies were obtained from 12 AITP patients (8 suffering from primary AITP, 3 suffering from AITP associated with SLE, 1 suffering from AITP associated with Sjögren's syndrome) by incubating patient plasma with purified GPIIb/IIIa at 4°C overnight and subsequently eluting, at room temperature for 15 min, in 0.2 mol/l glycine and 0.15 mol/l NaCl, pH 2.5. After centrifuging at 100,000 g for 30 min, the supernatant was neutralized with 1 mol/l Tris-HCl and dialysed overnight against Tris-buffered salt solution (TBS).

At the time of plasma withdrawal, all the patients were thrombocytopenic (platelet count < 150 × 10^9/l) and had normal or enlarged megakaryocytes in the bone marrow and were free of other detectable forms of immunothrombocytopenia.

1.2. Isolation of purified antigens

The antigens used were purified GPIIb/IIIa, a cytoplasmic fragment of GPIIIa (amino acids 721-744) and an extracellular fragment of GPIIIa (amino acids 468-690) (Beardsley, Blut 59 (1989), 47-51 and Phillips et al., Methods Enzymol. 215 (1992), 244-263).

1.3. Isolation of platelets for panning and immunoblotting

Platelet-enriched plasma was prepared by differential centrifugation from EDTA-anticoagulated blood samples taken from healthy human donors. The platelets were isolated by centrifuging at 2000 g for 15 min, then washed six times in citric acid buffer (pH 6.2) containing 50 mmol/l sodium citrate, 100 mmol/l NaCl and 125 mmol/l glucose, and finally resuspended in the same buffer.

The same enrichment protocol was used to obtain thrombasthenic platelets from a 14-year-old boy suffering from Glanzmann's type I thrombasthenia.

1.4. Monoclonal antibodies

Use was made of murine monoclonal antibodies which recognize the complexed form of GPIIb/IIIa and of antibodies which recognize GPIIb or GPIIIa selectively. These antibodies were isolated by means of customary immunization protocols using the corresponding antigens and are not AITP-associated. The isolation of such antibodies is described in Kouns et al. (J. Biol. Chem. 267 (1992), 18844-18851), Steiner et al. (Biochim. Biophys. Acta 1119 (1992), 12-21) and Häring et al. (Proc. Natl. Acad. Sci. USA 82 (1985), 4837-4841).

1.5. Phagemid library

A combinatorial Fab library was prepared in accordance with the method described by Vogel et al. (Eur. J. Immunol. 24 (1994), 1200-1207) using peripheral blood lymphocytes obtained from a healthy, preimmunized human donor. All the enzymes and oligonucleotides were obtained from Boehringer Mannheim GmbH (Mannheim, Germany) apart from the Taq polymerase (Perkin Elmer, NJ, USA). The primers for amplifying the H and L chains of the Fab molecules by PCR, the VCSM13 helper phage, and the Escherichia coli strain XL-Blue were obtained from Stratacyte (La Jolla, CA, USA). The phagemid pComb3 was obtained from Scripps Research Institute (La Jolla, CA, USA). The cloning, the transformation into XL-Blue cells and the preparation of phabs were carried out as described by Barbas III and Lerner, Methods: Companion Methods Enzymol. 2 (1991), 119). The phabs were precipitated with 4% (w/v) polyethylene glycol 8000 and 3% (w/v) NaCl and resuspended in PBS, pH 7.4. The resulting expression library contains 1×10^7 specificities.

1.6. Isolation of GPIIb/IIIa-specific phabs

GPIIb/IIIa-specific phabs were prepared by means of a total of 5 rounds of an affinity selection ("panning"). Following preabsorption (negative selection) with 5×10^7 thrombasthenic platelets, the phabs were incubated for 45 min with 10^8 normal platelets (positive selection). Bound phabs were then eluted with 0.05 mol/l sodium citrate, pH 2.5, and neutralized with 1 mol/l Tris buffer. After each round of panning, the enrichment of GPIIb/IIIa-specific phabs was monitored by titrating the phage-colony-forming units. After five rounds of selection, the eluted phabs were found to have been enriched by a factor of more than 100.

The pool of phabs obtained after the fourth round of selection was analysed more closely for its GPIIb/IIIa specificity. For this, 40 phab clones were selected at random and their binding specificity was ascertained in an immunodot assay. One µl of normal and thrombasthenic platelets (10^9 ml) [sic], and also purified GPIIb/IIIa (500 µg/ml), were added as drops onto nitrocellulose strips (Millipore Corporation, Bedford, MA, USA). The strips were blocked in TBS containing 0.15% casein (TBS-casein) and then incubated overnight together with the phabs, which had been diluted in TBS-casein. After three washes with TBS-0.1% Tween 20 (TBS-Tween), the bound phabs were detected with 4-chloro-1-α-naphthol (Merck, Darmstadt, Germany) following incubation with horseradish peroxidase-conjugated polyclonal rabbit anti-phage antibody (Vogel et al., loc. cit.) which had been diluted 1:1000 in TBS-casein.

The binding of phabs to platelets and purified GPIIb/IIIa was also tested after denaturing the proteins by heating (70°C) or by acid treatment (pH 2 with 0.5 N HCl) before dropping.

Of the 40 randomly selected clones, 23 (57.5%) reacted with GPIIb/IIIa, whereas 17 did not exhibit any binding. No binding of anti-GPIIb/IIIa [sic] to phabs was observed after denaturing the antigen by heat or pH 2 prior to the incubation, thereby demonstrating that intact GPIIb/IIIa is required for the phab binding. Determining the presence of Fab in negative phabs revealed that 15 of the clones (88%) did not contain any Fab molecules. The two Fab-positive clones which did not bind to GPIIb/IIIa could have a low binding affinity for GPIIb/IIIa.

1.7. Fab analysis

In order to test the positive phabs for kappa (κ), lambda (λ) and Fd chains, the anti-GPIIb/IIIa phabs were added as drops to nitrocellulose. The filters were incubated for 4 hours with peroxidase-labelled mouse anti-human λ, κ (The Binding Site Limited, Birmingham, England) and Fd antibodies (from the HP6045 myeloma cell line, ATCC1757, Rockville, MD, USA), which antibodies had been diluted 1:1000 in TBS-casein, and then developed by chemiluminescence (ECL, Amersham, Switzerland, Zurich, Switzerland). Testing 15 randomly selected anti-GPIIb/IIIa Fab clones for κ, λ and Fd chains showed that an Fd chain was present in 12 of the clones (80%) while the λ chain was present in all the clones.

Fab binding to GPIIb/IIIa on platelets was determined quantitatively by preincubating pool phabs with platelets at various concentrations. The supernatant was then analysed by an immunodot method. In this connection, it was established that from 1 to 3 × 10^4 phabs bind per platelet. This indicates that approximately 10 to 50% of the GPIIb/IIIa molecules per platelet can be occupied by phabs.

1.8. Characterizing the phab-binding epitopes

The epitope specificity of the phabs was determined by carrying out an inhibition test using a variety of monoclonal antibodies (see item 4 [sic]). 1 µl of thawed normal and thrombasthenic platelets (10^9/ml), purified GPIIb/IIIa (500 µg/ml), a peptide fragment of GPIIIa (amino acids 468-690, 500 µg/ml) and the cytoplasmic segment of GPIIb/IIIa (500 µg/ml) were in each case added as drops, in duplicate, onto nitrocellulose strips. After blocking, the phab clones (0.4 µg/ml Fab) were incubated overnight with or

without monoclonal antibody (1 μg/ml). The bound phabs were detected using peroxidase-labelled anti-phage antibody and 4-chloro-1-α-naphthol.

Two groups of phab clones were identified in these investigations. While Group A (5 clones) was inhibited moderately by a pool of all the antibodies, it was inhibited strongly by GPIIb/IIIa complex-specific antibodies. Anti-GPIIb antibodies had no effect. While Group B (10 clones) was inhibited completely by the pool of all the antibodies, it was inhibited to a lesser extent by the complex-specific antibody and also by the IIb-specific antibody. No group exhibited any reaction with GPIIIa-specific antibodies. The same results were obtained using either platelets or purified GPIIb/IIIa as the antigen. No phab binding to the cytoplasmic peptide or to the extracellular fragment of GPIIIa was found to occur.

A summary of these results is shown in Table 1.

Table 1

Inhibition of phab binding (mean value ± SD in %)				
Pools of monoclonal antibodies for inhibition	Group A phab clones (n = 5)		Group B phab clones (n = 10)	
	Platelets	Purified GPIIb/IIIa	Platelets	Purified GPIIb/IIIa
(1) Anti-GPIIB	0	0	49.1 ± 5.9	49.4 ± 9.2
(2) Anti-GPIIIa	0	0	0	0
(3) Anti-GPIIb/IIIa complex	77.8 ± 2.9	43.6 ± 2.1	58.6 ± 4.4	45.5 ± 8.0
Pool of all the antibodies (1)-(3)	47.6 ± 7.7	33.0 ± 10.8	95.9 ± 2.7	97.5 ± 7.5

1.9. Inhibition assays

The blocking, by the anti-GPIIb/IIIa phabs which had been found, of the binding of patient autoantibodies to GPIIb/IIIa was determined by means of inhibition assays. Two of the phab clones which had been identified as previously described (PDG16 and PDG31) were used for this purpose.

Serial dilutions of the eluted patient autoantibodies of from 1:3 to 1:1000 were analysed for binding to purified GPIIb/IIIa. This was done by performing an immunodot assay. 100 ng of purified GPIIb/IIIa were in each case added as drops, in triplicate, onto nitrocellulose strips and the filters were then blocked with TBS-casein. In order to block the binding of AITP autoantibodies to GPIIb/IIIa with phabs, the strips were incubated with 10^{11} phabs for 1 h and then incubated with varying dilutions of AITP autoantibodies for 4 h. Bound autoantibodies were detected using peroxidase-labelled anti-human IgG-Fc antibodies and ECL.

Anti-GPIIb/IIIa phabs inhibited the binding of autoantibodies obtained from 8 AITP patients. The inhibition range [sic] was [sic] from 10 to 46%, from 32 to 60% and from 20 to 67% for PTG16, PTG31 and the pool of the two phabs, respectively. These phabs had no effect on the binding of autoantibodies obtained from 4 AITP patients. Both groups contained autoantibodies derived from patients suffering from primary AITP and from disease-associated AITP.

The results which were obtained are summarized in Table 2.

Table 2

	Inhibition of the binding to purified GPIIb/IIIa by (%)		
AITP patient	Phab clone PDG16	Phab clone PDG31	Pool of the two phab clones
WS16	13	19	40
WS37	14	20	36
KC	24	22	28
KK	22	22	40
KP	10	36	60
WS2	25	55	65
KS	60	56	64
KL	0	15	10
KG	0	0	0
KM	0	0	0
KE	0	0	0
KR	0	0	0

1.10 DNA sequence analysis

Plasmid DNA was purified from four Group A phab clones and 4 group [lacuna] clones using the Nukleobond® AX PC 20 purification kit (Macherey-Nagel AG, Oensingen, Switzerland).

The nucleic acid sequencing was carried out on an ABI373A sequencing system using a PRISM Ready Reaction DyeDeoxy Terminator Cycle Sequencing kit. The primers were obtained from Microsynth, Balgach, Switzerland. The following primers were used for sequencing the H chain: Chγ1 (5'-CGC TGT GCC CCC AGA GGT-3') and PCH (5'-GGC CGC AAA TTC TAT TTC AAG G-3'). The following primers were used for sequencing the L chain: Cλ (5'-GAG ACA CAC CAG TGT GGC-3'), Ck (5'-CAC AAC AGA GGC AGT TCC-3') and PCL(5'-CTA AAC TAG CTA GTC TCC-3'). The amino acid sequences which were deduced from the DNA

sequence were compared with GenEMBL-Genbank and strain lines were assigned to VH and Vλ families.

The VH and Vλ nucleotide sequences of the 4 phab clones from each group (Group A: PDG7, PDG8, PDG10 and PDG16; Group B: PDG13, PDG17, PDG31 and PTG37 [sic]) were analysed by automated sequencing and compared with known strain line gene sequences (Tables 3 and 4). There was 100% homology in the deduced amino acid sequences of the H and L chains within each group. By contrast, the homology between Group A and Group B was only 36.9% in the case of the H chain and 81.9% in the case of the L chain amino acid sequences.

In the H chain, Group A clones exhibit the highest degree of sequence identity with the strain line gene VH4.11 of the V_H4 family (Sanz, et al. EMBO J. 8 (1989), 3741-3748). There were 7 amino acid differences in the framework region (FR) and 8 in the complement-determining [sic] region (CDR). Group B clones differed from the mostly homologous 1.9III strain line sequence of the V_H3 family (Berman et al., EMBO J. 7 (1988), 727-738) in four amino acids in the FR and one in the CDR.

In the L chain, the Group A and Group B clones exhibited the highest homology with the DPL2 strain line gene sequence of the $V_λ1$ family (Williams and Winter, Eur. J. Immunol. 323 (1993), 1456). There were nine amino acid differences in FR and ten in CDR in the case of the Group A clones, and one in FR and two in CDR in the case of the Group B clones. The results which were obtained are summarized in Tables 3 and 4.

Table 3



FR: framework region; CDR: complement-determining [sic] region. The top sequences (VH4.11; 1.9III; DPL2) are given for comparative purposes and in each case represent the deduced amino acid sequence for the most closely related published strainline gene sequence. Dashes denote identity. M85255 refers to the EMPL/GenBank reference number and denotes the deduced amino acid sequence of the human anti-GPIIb autoantibody 2E7 (Kunicki et al., J. Autoimmun. 4 (1991), 433-446). In the case of the heavy chain, the first three amino acids (QVK) are specified by the pComb3 vector sequence.

Table 4 shows the assignment of the Group A and Group B clones to known strainline V gene sequences in accordance with the amino acid homology

	Heavy chain			Light chain		
PDG phab clones	V_H family	Strain-line gene	Homology (%)	V_λ family	Strain-line gene	Homology (5)
Group A: 7,8,10, 16	V_H4	$V_{H4}.11$	84.3	$V_\lambda I$	DPL2	81.4
Group B: 13,17, 31,37	V_H3	1.9III	95.1	$V_\lambda I$	DPL2	97.1

2. Identifying antiidiotypic antibody sequences

2.1 Phab clones AI-X

The phagemids technique was used to identify sequences for antiidiotypic antibodies in accordance with the method described in Example 1. The clone PDG16, which was selected in Example 1, was used as the antigen. There was no negative preselection.

Use was made of a pool of combinatorial phab libraries [lacuna] the specificities of a nonimmune library of peripheral B lymphocytes and of a library of peripheral lymphocytes which had been immobilized with red blood cells, and also of a nonimmune library of B lymphocytes obtained from tonsils.

The pool of phabs which was obtained after the fourth round of panning was analysed. For this, 40 phab clones were selected at random and their binding specificities were determined. 25 of the selected clones reacted with anti-GPIIb/IIIa phab. These antiidiotypic phab clones belong to two groups: Group I (three clones) only

reacted with Group A autoantibody phab clones (PDG 7, 8, 10 and 16), whereas the Group II phab clones (22 clones in all) reacted with the Group A and Group B phab clones, with murine monoclonal anti-GPIIb/IIIa antibodies, with purified serum immunoglobulin (IVIgG) or $F(ab')_2$ fragments thereof, and with anti-IgE Fab. 14 phab clones (Group III) did not react with any of the substances mentioned. One Group IV phab clone only reacted with anti-GPIIb/IIIa antibodies. The results of these specificity assays are summarized in Table 5a.

A DNA sequence analysis carried out on Group I phab clones (AI-X16, 17 and 24) showed complete identity in the heavy-chain-encoding sequences apart from one amino acid in the CDR2 region and complete identity in the light-chain-encoding sequences. A comparison with known strainline gene sequences showed approx. 85% homology with the VH3 H chain sequence and approx. 90% homology with the V-λII L chain family sequence. A DNA sequence analysis of the H chain gene was carried out on one representative of each of the Group II, III and IV phab clones. The results of this sequence analysis, and of the comparison with known strainline gene sequences, are summarized in Tables 6 and 7a.

The result of an inhibition assay is depicted in Fig. 1. The inhibition of the binding of AI-X17 to PDG-A by purified GPIIb/IIIa was determined by means of an immunodot assay. 660 and 220 ng of PDG-A phab, respectively, were added to nitrocellulose. The antigen was incubated for 2 h with GPIIb/IIIa at concentrations in the range from 50 µg/ml to 50 ng/ml, and with a buffer solution as control, and then incubated for a further two hours with the phage clone AI-X17 (final concentration 10^{12}/ml). The bound phages were detected using peroxidase-conjungated polyclonal rabbit anti-phage antibody and electrochemiluminescence.

It was found that the AI-X17 phab (Group I) is able to inhibit the binding of Group A antibody phabs (PDG-X) to the IIb/IIIa glycoprotein. This signifies that AI-X17 recognizes the antigen-binding site on PDG-A.

Another clone AI-X2 which binds to PDG-A was sequenced. Like clones AI-X20, 39 and 40, this clone only has a heavy chain and no light chain. The heavy chain is able to bind on its own, possibly as a dimer, to the antigen, i.e. PDG-A, with adequate specificity and affinity.

2.2 Phab clones AI-B

The phagemid technique was used to identify sequences of other antiidiotypic antibodies in accordance with the method described in Example 2.1. A clone PDG-B which was selected in Example 1 was used as the antigen.

In all, 40 phab clones were selected and their binding specificity determined. 34 of the selected clones reacted with anti-GPIIb/IIIa PHAB. These antiidiotypic phab clones belonged to three groups:

Group I (14 clones) only reacted with the Group B antibody phab clones, whereas the Group II phab clones (8 clones in all) reacted with both Group A and Group B phab clones. The Group III phab clones (12 clones in all) additionally reacted with murine monoclonal anti-GPIIb/IIIa antibodies, with purified serum immunoglobulin (IVIgG) or $F(ab')_2$ fragments thereof, and with anti-IgE Fab. Six phab clones (Group IV) did not react with any of the substances mentioned. The results of these specificity assays are summarized in Table 5b.

The result of carrying out a DNA sequence analysis on Group I phab clones (AI-14, 18, 24 and 38) is summarized in Tables 6 and 7b. Clones AI-B14, 18 and 38 only had a heavy chain.

AI-B14 and 17 are identical. AI-B34 and 40 are likewise identical with AI-B18.

The inhibition of the binding of PDG-B to platelets by AI-B phabs is depicted in Fig. 2. This was determined by means of flow-cytometric analysis. For this, a platelet-rich plasma (10^7 platelets in all) was incubated with biotinylated PDG-B in the presence or absence of AI-B phabs and using helper phages as the control. The platelets were fixed with paraformaldehyde and bound PDG-B was detected with R-phycoerythrin (RPE)-labelled streptavidin. 10,000 events were counted in a FACScan appliance and the mean value of the fluorescence (± SD) was recorded. The strongest inhibition (> 60%) was achieved with clones AI-B18, 24 and 38. The inhibition of the binding shows that AI-B clones interact with the antigen-binding site on PDG-B.

Table 5a

AIX phab clones		Binding to PDG A	PDGB	anti-IgE Fab	anti-GPIIb/IIIa mAb	SG	$F(ab')_2$
Group I							
16,17,24	3	+	-	-	-	-	-
Group II							
1,2,3,4,5,6,7,9,11, 13,14,23,26,27,28,29, 33,35,36,37,38,40	22	+	+	+	+	+	+
Group III							
8,10,12,15,18,19,21, 22,25,30,31,32,34,39	14	-	-	-	-	-	-
Group IV							
20	1	-	-	-	+	-	-

Table 5b

AI-B phab clones n	Binding to					
	PDG-X	PDG-B	anti-IgE Fab	anti-GPIIb/IIIa mAb	IvIgG	IvIgG F(ab')$_2$
14 (AI-B5,7,8,14,17, 18,23,24,30,31,33, 34,38,40)	-	+	-	-	-	-
8	+	+	-	-	-	-
12	+	+	+	+	+	+
6	-	-	-	-	-	-

Table 6

anti-Id phage clones / antiidiotypic phab clones (AI-X and AI-B)	H chain			L chain		
	V_H family	Strainline gene	Homology (%)*	V_λ family	Strainline gene	Homology (%)*
AI-X16, AI-X24	V_H3	DP47	88	$V_\lambda2$	DPL10	88
AI-X17	V_H3	DP47	87	$V_\lambda2$	DPL10	88
AI-X39	V_H3	DP49	94	-	-	-
AI-X40	V_H3	DP31	95	-	-	-
AI-X20	V_H4	DP71	78	-	-	-
AI-B14, AI-B17	V_H3	DP46	91	-	-	-
AI-B18	V_H1	DP10	85	-	-	-
AI-B24	V_H3	DP49	81	$V_\lambda3$	3h	82
AI-B38	V_H1	DP5	98	-	-	-

* Highest homology (in %) of the amino acid sequences of the respective phab clones with sequences of known strainline V genes

Table 7a

A. Heavy chains



B. Light chains



FR: framework region; CDR: complement-determining [sic] region. The top sequences (DP47, DP49, DP31, DP71 and DPL10) are given for comparative purposes and represent the most closely related known strainline sequences. Dashes denote identity. In the case of the heavy chain, the first three amino acids (QVK) are specified by the pComb3 vector sequence.

Table 7b

A. Heavy chains



B. Light chains



FR: framework region; CDR: complement-determining [sic] region. The top sequences (DP46, DP10, DP49, DP5 and VL3h) are given for comparative purposes and represent the most closely related known strainline sequences. Dashes denote identity. In the case of the heavy chain, the first three amino acids (QVK) are specified by the pComb3 vector sequence.

3. Effect of autoantibody polypeptides on the binding of fibrinogen to blood platelets

3.1 Methods

Analysis of the binding of Fab to EDTA-pretreated blood platelets

A blood platelet-rich plasma was incubated with 10 mM EDTA for 30 min. Biotinylated PDG-B and PDG-A polypeptides were added and the mixture was incubated at room temperature for 1 h. The binding of PDG-A and PDG-B to blood platelets was measured by flow-cytometric analysis using phycoerythrin-labelled streptavidin.

Aggregation experiments

Blood platelet-rich plasma ($250 \times 10^9/l$) was prepared freshly and maintained under 5% CO_2. The plasma was activated by different dilutions of ADP (maximum concentration 410 µM) in the absence or presence of PDG-A or PDG-B (maximum quantity 10 µg of Fab). The aggregation was measured in a Rodell 300BD-5 aggregometer (Baxter AG, Düdingen, Switzerland). In subsequent experiments, polyclonal anti-Fab antiserum was added to the activated platelets after PDG-A or PDG-B had been added.

Fibrinogen binding test

Wells of ELISA plates were coated with 0.5 µg/ml GPIIb/IIIa and blocked with 3.5% bovine serum albumin in Tris-buffered salt solution. Fibrinogen (Kabi Diagnostics, Stockholm, Sweden) was then added at different concentrations (maximally 0.08 µg/ml) in the absence or in the presence of PDG-A, PDG-B or anti-IgE Fab as the control (maximum concentration 23 µg/ml).

The bound fibrinogen was measured with rat anti-human fibrinogen antibody, biotinylated mouse anti-rat antibody and a conjugate consisting of streptavidin and biotinylated horseradish peroxidase (Amersham Pharmacia Biotech Europe GmbH, Dübendorf, Switzerland) and using an ELISA Easy Reader (EAR340AT, SLT Instruments, Austria) at 405 nm.

Competition assay using the monoclonal antibody 7E3 and the antibody fragment ReoPro®

Platelet-rich plasma (230×10^9/l) was incubated for 1.5 h with PDG-B or PDG-A (200 and 400 µg/ml, respectively) with or without the murine monoclonal antibody 7E3 or its Fab fragment ReoPro® (total quantity of Fab in the range from 10^{14} to 10^{10}). After fixing with an equal volume of 1% paraformaldehyde, the binding of PDG-B and PDG-A to platelets was measured by flow-cytometric analysis using phycoerythrin-labelled streptavidin.

3.2 Results

The recombinant anti-GPIIb/IIIa Fab autoantibody fragments which were tested do not exhibit any binding to blood platelets which had been pretreated with 10 mM EDTA. This shows that the autoantibody fragments only recognize an antigen whose confirmation is intact (Fig. 3).

In aggregation experiments using platelet-enriched plasma, neither PDG-A nor PDG-B inhibited the aggregation. In a fibrinogen-binding test in which the concentration of fibrinogen was from 10^4 to 10^6 times lower than in serum, PDG-A and PDG-B completely inhibited the fibrinogen binding (Fig. 4). No inhibition occurred when anti-IgE Fab, which had been obtained by a similar enrichment protocol, was used as

the control. These results show that both PDG-A and PDG-B interact powerfully with the fibrinogen-binding site on GPIIb/IIIa.

In investigations carried out with the murine monoclonal anti-GPIIb/IIIa antibody 7E3 and its commercially available Fab fragment ReoPro®, both of which inhibit the binding of fibrinogen to activated GPIIb/IIIa, the binding of PDG-B to blood platelets was found to be inhibited selectively and completely (Figures 5 to 7). By contrast, the binding of PDG-A to blood platelets was not inhibited significantly either by 7E3 or by ReoPro®.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME:
ASAT AG Applied Science & Technology

(B) STREET: Baarerstrasse 77

(C) CITY: Zug

(E) COUNTRY: Switzerland

(F) POSTAL CODE: 6302

(ii) TITLE OF INVENTION: Recombinant antibodies

(iii) NUMBER OF SEQUENCES: 30

(iv) COMPUTER-READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0,
Version #1.30 (EPO)

(vi) ORIGINAL APPLICATION DATA:

(A) APPLICATION NUMBER: DE 19723904.8

(B) APPLICATION DATE: 06-JUN-1997

(vi) ORIGINAL APPLICATION DATA:

(A) APPLICATION NUMBER: DE 19755227.7

(B) APPLICATION DATE: 12-DEC-1997

(vi) ORIGINAL APPLICATION DATA:

(A) APPLICATION NUMBER: DE 19820663.1

(B) APPLICATION DATE: 08-MAY-1998

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 357 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) NOTATION: 1..357

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

```
CAG GTG AAA CTG CTC GAG TCG GGC CCA GGA CTG GTG AAG CCT TCG GAG      48
Gln Val Lys Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
  1               5                  10                  15

ACC CTG TCC CTC AAC TGC ACT GTC TCT GGT CGC TCC ATC AGT GGT TAC      96
Thr Leu Ser Leu Asn Cys Thr Val Ser Gly Arg Ser Ile Ser Gly Tyr
             20                  25                  30

TCT TGG AGA TGG ATC CGG CAG TCT CCA GGG AAG GGA CTA GAG TGG ATT     144
Ser Trp Arg Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Ile
         35                  40                  45

GGG GAT ATC TCT TAT AGT GGG AGT ACC AAG TAC AAA CCC TCC CTC AGG     192
Gly Asp Ile Ser Tyr Ser Gly Ser Thr Lys Tyr Lys Pro Ser Leu Arg
     50                  55                  60

AGT CGA GTC ACC CTG TCA GTA GAC ACG TCC AAG AAC CAG TTC TCC CTG     240
Ser Arg Val Thr Leu Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
 65                  70                  75                  80

AAG CTG AAT TCG GTG ACC GCT GCG GAC ACG GCC GTC TAT TAC TGT GCG     288
Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
                 85                  90                  95

CGA GTC TTG CCC TTT GAC CCG ATC TCG ATG GAC GTC TGG GGC AAA GGG     336
Arg Val Leu Pro Phe Asp Pro Ile Ser Met Asp Val Trp Gly Lys Gly
            100                 105                 110

ACC ACG GTC ACC GTC TCC TCA                                         357
Thr Thr Val Thr Val Ser Ser
        115
```

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 119 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

```
Gln Val Lys Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1               5                  10                  15

Thr Leu Ser Leu Asn Cys Thr Val Ser Gly Arg Ser Ile Ser Gly Tyr
            20                  25                  30

Ser Trp Arg Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45

Gly Asp Ile Ser Tyr Ser Gly Ser Thr Lys Tyr Lys Pro Ser Leu Arg
    50                  55                  60

Ser Arg Val Thr Leu Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65                  70                  75                  80

Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
                85                  90                  95

Arg Val Leu Pro Phe Asp Pro Ile Ser Met Asp Val Trp Gly Lys Gly
            100                 105                 110

Thr Thr Val Thr Val Ser Ser
        115
```

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 333 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..333

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

```
GTG GTG ACT CAG CCA CCC TCA GCG TCT GGG ACC CCC GGG CAG TGG GTC          48
Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Trp Val
 1               5                  10                  15

GCC ATC TCT TGT TCT GGG AGC AGC TCC AAC ATC AGA AGT AAT CCT GTT          96
Ala Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Arg Ser Asn Pro Val
            20                  25                  30

AGC TGG TAT CAC CAG GTC CCA GGC ACG GCC CCC AAA CTC CTC ATC TTT         144
Ser Trp Tyr His Gln Val Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe
        35                  40                  45

GGT AGT CAT CAG CGG CCC TCA GGG GTC CCT GAC CGA TTC TCT GGC TCC         192
Gly Ser His Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser
    50                  55                  60

AAG TCG GGC ACC TCC GCC TCC CTG GCC ATC CGT GGG CTC CAA TCT GGG         240
Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Arg Gly Leu Gln Ser Gly
65                  70                  75                  80
```

```
GAT GCT GGT GAC TAT TAC TGT GCA ACA TGG GAT GAC GGC CTC AAT GGT        288
Asp Ala Gly Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Gly Leu Asn Gly
200                 205                 210                 215

CCG GTG TTC GGC GGA GGG ACC AAG CTG ACC GTC CTA AGT CAG CCC            333
Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ser Gln Pro
                220                 225                 230
```

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 111 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

```
Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Trp Val
 1               5                  10                  15

Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Arg Ser Asn Pro Val
            20                  25                  30

Ser Trp Tyr His Gln Val Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe
        35                  40                  45

Gly Ser His Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser
    50                  55                  60

Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Arg Gly Leu Gln Ser Gly
65                  70                  75                  80

Asp Ala Gly Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Gly Leu Asn Gly
                85                  90                  95

Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ser Gln Pro
            100                 105                 110
```

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 369 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..369

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

```
CAG GTG AAA CTG CTC GAG TCT GGG GGA GGC GTG GTC CAG CCT GGG AGG          48
Gln Val Lys Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
            115                 120                 125

TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT AGC TAT          96
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
        130                 135                 140

GCT ATG CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAG TGG GTG         144
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
    145                 150                 155

GCA GTT ATA TCA TAT GAT GGA AGC AAT AAA TAC TAC GCA GAC TCC GTG         192
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
160                 165                 170                 175

AAG GGC CGA TTC GCC ATC TCC AGA GAC AAT TCC AAG AAC ACG CTG TAT         240
Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
                180                 185                 190

CTG CAA ATG AAC AGC CTG AGA GCT GAG GAC ACG GCT GTG TAT TAC TGT         288
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
            195                 200                 205

GCG AGA GCG CTG GGG AGC TGG GGG GGT TGG GAC CAC TAC ATG GAC GTC         336
Ala Arg Ala Leu Gly Ser Trp Gly Gly Trp Asp His Tyr Met Asp Val
        210                 215                 220

TGG GGC AAA GGG ACC ACG GTC ACC GTC TCC TCA                             369
Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser
    225                 230
```

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 123 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

```
Gln Val Lys Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1               5                  10                  15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
            20                  25                  30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
    50                  55                  60

Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95

Ala Arg Ala Leu Gly Ser Trp Gly Gly Trp Asp His Tyr Met Asp Val
            100                 105                 110

Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser
        115                 120
```

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 333 base pairs
(B) TYPE: nucleotide
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..333

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

```
GTG GTG ACT CAG CCA CCC TCA GCG TCT GGG ACC CCC GGG CAG AGG GTC      48
Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val
 125                 130                 135

ACC ATC TCT TGT TCT GGA AGC AGC TCC AAC ATC GGA AGT AAT ACT GTA      96
Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val
140                 145                 150                 155

AAC TGG TAC CAG CAG CTC CCA GGA ACG GCC CCC AAA CTC CTC ATC TAT     144
Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr
                160                 165                 170

AGT AAT AAT CAG CGG CCC TCA GGG GTC CCT GAC CGA TTC TCT GGC TCC     192
Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser
            175                 180                 185

AAG TCT GGC ACC TCA GCC TCC CTG GCC ATC AGT GGG CTC CAG TCT GAG     240
Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu
        190                 195                 200

GAT GAG GCT GAT TAT TAC TGT GCA GCA TGG GAT GAC AGC CTG AAT GGT     288
Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly
    205                 210                 215

TGG GTG TTC GGC GGA GGG ACC AAG CTG ACC GTC CTA GGT CAG CCC         333
Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro
220                 225                 230
```

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

```
Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val
 1               5                  10                  15

Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val
            20                  25                  30

Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr
        35                  40                  45

Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser

    50                  55                  60

Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu
65                  70                  75                  80

Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly
                85                  90                  95

Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro
            100                 105                 110
```

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 369 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..369

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

```
CAG GTG AAA CTG CTC GAG TCT GGG GGA GGC TTG GTT CAC CCC GGG GGG          48
Gln Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val His Pro Gly Gly
            115                 120                 125

TCC CTG AGA CTC TCT TGT GCA GCC TCT GGA TTT ACG TTT GAC AAC TTT          96
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asn Phe
        130                 135                 140

GCC ATG AGC TGG GTC CGC CAG GCT CCA GGG AAG GGG CTG GAG TGG GTC         144
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
    145                 150                 155

TCA GGC ATT AGT GGT GGT GGT CTT TTG ACA CAC TAC GCA GAC TCC GTG         192
Ser Gly Ile Ser Gly Gly Gly Leu Leu Thr His Tyr Ala Asp Ser Val
160                 165                 170                 175

AAG GGC CGG TTC ACC ATC TCC AGA AAC AAT TCC AGG AAC ACT GTA TAC         240
Lys Gly Arg Phe Thr Ile Ser Arg Asn Asn Ser Arg Asn Thr Val Tyr
                180                 185                 190

CTA CAA ATG AAC AGC CTG AGA GCC GAA GAC ACG GCC GTG TAT TAT TGT         288
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
            195                 200                 205
```

```
GTG AGA GAT CTG GGC TAT AGA GTA CTT TCG ACT TTT ACT TTT GAT ATC      336
Val Arg Asp Leu Gly Tyr Arg Val Leu Ser Thr Phe Thr Phe Asp Ile
        210                 215                 220

TGG GGC CAG GGG ACA AAG GTC ACC GTC TCT TCA                      369
Trp Gly Gln Gly Thr Lys Val Thr Val Ser Ser
    225                 230
```

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 123 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

```
Gln Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val His Pro Gly Gly
 1               5                  10                  15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asn Phe
            20                  25                  30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45

Ser Gly Ile Ser Gly Gly Gly Leu Leu Thr His Tyr Ala Asp Ser Val
    50                  55                  60

Lys Gly Arg Phe Thr Ile Ser Arg Asn Asn Ser Arg Asn Thr Val Tyr
65                  70                  75                  80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95

Val Arg Asp Leu Gly Tyr Arg Val Leu Ser Thr Phe Thr Phe Asp Ile
            100                 105                 110

Trp Gly Gln Gly Thr Lys Val Thr Val Ser Ser
        115                 120
```

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 375 base pairs
(B) TYPE: nucleotide
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..375

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

```
GTG GTG ACT CAG CCT GCC TCC GTG TCT GGG TCT CCT GGA CAG TCG ATC          48
Val Val Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile
    125                 130                 135

ACC ATC TCC TGC ACT GGA ACC AGC AGT GCT ATT GGG AAT TAT AAC TTT          96
Thr Ile Ser Cys Thr Gly Thr Ser Ser Ala Ile Gly Asn Tyr Asn Phe
140                 145                 150                 155

GTC CCC TGG TAC CAA CAG CAC CCA GGC AAA GCC CCC AAA CTC ATG ATT         144
Val Pro Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile
                160                 165                 170

TAT GAG GGC AGT AAG CGG CCC TCA GGG GTT TCT AAT CGC TTC TCT GGC         192
Tyr Glu Gly Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly
            175                 180                 185

TCC AAG TCT GGC AAC ACG GCC TCC CTG ACA ATC TCT GGG CTC CAG GCT         240
Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala
        190                 195                 200

GAG GAC GAG GCT GAG TAT TAC TGC TGC TCA TAT GTT CAT AGT AGC ACT         288
Glu Asp Glu Ala Glu Tyr Tyr Cys Cys Ser Tyr Val His Ser Ser Thr
    205                 210                 215

AAT TGG GTG TTC GGC GGA GGG ACC AAG CTG ACC GTC CTA GGT CAG CCC         336
Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro
220                 225                 230                 235

AAG GCT GCC CCC TCG GTC ACT CTG TTC CCA CCC TCC TCT                     375
Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser
                240                 245
```

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 125 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

```
Val Val Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile
 1               5                  10                  15

Thr Ile Ser Cys Thr Gly Thr Ser Ser Ala Ile Gly Asn Tyr Asn Phe
            20                  25                  30

Val Pro Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile
        35                  40                  45

Tyr Glu Gly Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly
    50                  55                  60

Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala
65                  70                  75                  80

Glu Asp Glu Ala Glu Tyr Tyr Cys Cys Ser Tyr Val His Ser Ser Thr
                85                  90                  95
```

Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro
100 105 110

Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser
115 120 125

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 366 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..366

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

```
CAG GTG AAA CTG CTC GAG TCA GGA CCA GGA CTG GTG AAG CCC TCG GAG      48
Gln Val Lys Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
            130                 135                 140

ACC CTG TCT CTC ACC TGC ACT GTC TCT GAT GTC TCC ATC AGA AGT CAT      96
Thr Leu Ser Leu Thr Cys Thr Val Ser Asp Val Ser Ile Arg Ser His
        145                 150                 155

TAC TGG AGT TGG CTC CGG CAG CCC CCA GGG AAG GGA CTG GAG TGG ATT     144
Tyr Trp Ser Trp Leu Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
    160                 165                 170

GGG TTT ATC TAT GAC GGT GCG AGA ACC AGG TTC AAC CCC TCC CTC AGG     192
Gly Phe Ile Tyr Asp Gly Ala Arg Thr Arg Phe Asn Pro Ser Leu Arg
175                 180                 185

AGT CGA GTC TCC CTT TCA ATG GAC CCA TCC AAG AAG CAG TTT TCC CTG     240
Ser Arg Val Ser Leu Ser Met Asp Pro Ser Lys Lys Gln Phe Ser Leu
190                 195                 200                 205

AAA CTG GGG TCT GTG ACC GCT GCG GAC TCG GCC GTC TAC TAC TGT GCG     288
Lys Leu Gly Ser Val Thr Ala Ala Asp Ser Ala Val Tyr Tyr Cys Ala
                210                 215                 220

AGA GAC GCG GAT GGA GAT GGC TTC AGC CCA TAC TAC TTT CCC TAC TGG     336
Arg Asp Ala Asp Gly Asp Gly Phe Ser Pro Tyr Tyr Phe Pro Tyr Trp
            225                 230                 235

GGC CAG GGA ATC CCG GTC TCC GTC TCC TCG                             366
Gly Gln Gly Ile Pro Val Ser Val Ser Ser
        240                 245
```

(2) INFORMATION FOR SEQ ID NO: 14

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 122 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

```
Gln Val Lys Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1               5                  10                  15

Thr Leu Ser Leu Thr Cys Thr Val Ser Asp Val Ser Ile Arg Ser His
            20                  25                  30

Tyr Trp Ser Trp Leu Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45

Gly Phe Ile Tyr Asp Gly Ala Arg Thr Arg Phe Asn Pro Ser Leu Arg
    50                  55                  60

Ser Arg Val Ser Leu Ser Met Asp Pro Ser Lys Lys Gln Phe Ser Leu
65                  70                  75                  80

Lys Leu Gly Ser Val Thr Ala Ala Asp Ser Ala Val Tyr Tyr Cys Ala
                85                  90                  95

Arg Asp Ala Asp Gly Asp Gly Phe Ser Pro Tyr Tyr Phe Pro Tyr Trp
            100                 105                 110

Gly Gln Gly Ile Pro Val Ser Val Ser Ser
        115                 120
```

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 372 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..372

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

```
CAG GTG AAA CTG CTC GAG TCT GGG GGA GGC GTG GTC CAC CCT GGG AGG      48
Gln Val Lys Leu Leu Glu Ser Gly Gly Gly Val Val His Pro Gly Arg
        125                 130                 135

TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT AGC TAT      96
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
    140                 145                 150

ACT ATG CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAG TGG GTG     144
Thr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
155                 160                 165                 170

GCA CTT ATA TCA TAT GAT GGA AGC AAT AAA TAC TAC GCA GAC TCC GTG     192
Ala Leu Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
                175                 180                 185
```

```
AAG GGC CGA TTC GCC ATC TCC AGA GAC AAT TCC AAG AAC ACG CTA TAT      240
Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
            190                 195                 200

CTG CAA ATG AAC AGC CTG AGA GCT GAG GAC ACG GCT GTG TAT TAC TGT      288
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
        205                 210                 215

GCG AAA GAT GGC CGG AGT GGG AGC TAC GCC AGG TTC GAC GGT ATG GAC      336
Ala Lys Asp Gly Arg Ser Gly Ser Tyr Ala Arg Phe Asp Gly Met Asp
    220                 225                 230

GTC TGG GGC CAA GGG ACC ACG GTC ACC GTC TCC TCA                      372
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
235                 240                 245
```

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 124 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

```
Gln Val Lys Leu Leu Glu Ser Gly Gly Gly Val Val His Pro Gly Arg
 1               5                  10                  15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
            20                  25                  30

Thr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45

Ala Leu Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
    50                  55                  60

Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95

Ala Lys Asp Gly Arg Ser Gly Ser Tyr Ala Arg Phe Asp Gly Met Asp
            100                 105                 110

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
        115                 120
```

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 372 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..372

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

```
CAG GTG AAA CTG CTC GAG TCT GGG GGA GGC TTG GTA CAG CCT GGC AGG      48
Gln Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
125                 130                 135                 140

TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTT GAT GAT TAT      96
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
                145                 150                 155

GCC CTG CAC TGG GTC CGT CAA GCT CCA GGG AAG GGC CTG GAG TGG GTC     144
Ala Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
            160                 165                 170

TCA GGT ATT AGT TGG GAT AGT GGT ACC ATA GGC TAT GCG GAC TCT GTG     192
Ser Gly Ile Ser Trp Asp Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val
        175                 180                 185

AAG GGC CGA TTC ACC ATC TCC AGA GAC AAC GCC AAG AAC TCC CTG TAT     240
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
    190                 195                 200

CTG CAA ATG AAC AGT CTG AGA GCT GAG GAC ACG GCC TTG TAT TAC TGT     288
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys
205                 210                 215                 220

GTA AAA GAT ATG GGG TCT TCG GTA GTG GCT ACG TAC AAT GCT TTT GAT     336
Val Lys Asp Met Gly Ser Ser Val Val Ala Thr Tyr Asn Ala Phe Asp
                225                 230                 235

ATC TGG GGC CAA GGG ACA ATG GTC ACC GTC TCT TCA                     372
Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
            240                 245
```

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 124 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

```
Gln Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
 1               5                  10                  15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
            20                  25                  30

Ala Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45

Ser Gly Ile Ser Trp Asp Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val
    50                  55                  60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65                  70                  75                  80
```

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95

Val Lys Asp Met Gly Ser Ser Val Val Ala Thr Tyr Asn Ala Phe Asp
100 105 110

Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
115 120

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 360 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA for mRNA

(vii) IMMEDIATE SOURCE:

(B) CLONE(E): AI-X2

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..360

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

```
CAG GTG AAA CTG CTC GAG TCA GGC CCA GGA CTG GTG AAG CCT TCG GAG      48
Gln Val Lys Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
125                 130                 135                 140

ACC CTG TCC CTC ACC TGC ACT GTC TCT GGT GGC TCC TTC AGT ACT TAC      96
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Phe Ser Thr Tyr
                145                 150                 155

TAT TGG AGC TGG ATC CGG CAG CCC CCA GGG AAG GGA CTG GAG TGG ATT     144
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
            160                 165                 170

GGG TAT ATC TAT TAC AGT GGG AAC ACC AAC TAC AAC CCC TCC CTC AAG     192
Gly Tyr Ile Tyr Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys
        175                 180                 185

AGT CGA GCC ACC ATA TCA GTA GAC ACG TCC AAG AAC CAG TTC TCC CTG     240
Ser Arg Ala Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
    190                 195                 200

AAG CTG AGC TCT GTT ACC GCC GCA GAC ACG GCC GTA TAT TAC TGT GCG     288
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
205                 210                 215                 220

AGA CTG CGT AAC GAT GGC TGG AAT GAT GGC TTT GAT ATC TGG GGC CAA     336
Arg Leu Arg Asn Asp Gly Trp Asn Asp Gly Phe Asp Ile Trp Gly Gln
                225                 230                 235

TGA                                                                 360
```

GGG ACA ATG GTC ACC GTC TCT TCA 360
Gly Thr Met Val Thr Val Ser Ser
240

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 120 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Gln Val Lys Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Phe Ser Thr Tyr
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Tyr Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60

Ser Arg Ala Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95

Arg Leu Arg Asn Asp Gly Trp Asn Asp Gly Phe Asp Ile Trp Gly Gln
100 105 110

Gly Thr Met Val Thr Val Ser Ser
115 120

(2) INFORMATION FOR SEQ ID NO: 21

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 369 base pairs
(B) TYPE: nucleotide
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA for mRNA

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE(E): AI-B14

(viii) POSITION IN THE GENOME:

(A) CHROMOSOME/SEGMENT: 14

(B) MAP POSITION: q32.3

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..369

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

```
CAG GTG AAA CTG CTC GAG TCT GGG GGA GGC GTG GTC CAG CCT GGG AGG      48
Gln Val Lys Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
                125                 130                 135

TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT GAC TAT      96
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
            140                 145                 150

GGC ATG CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAG TGG GTG     144
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        155                 160                 165

GCA GCT ATA TCA TAT GAT GGA AGT AAC AAA TAC TAT GCA GAC TCC GTG     192
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
    170                 175                 180

AAG GGC CGA TTC TCC ATC TCC AGA GAC AAT TCC AAC AAT ACG CTA TAT     240
Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ser Asn Asn Thr Leu Tyr
185                 190                 195                 200

CTG CAA ATG AGC ACC CTG AGA GCT GAG GAC ACG GCT GTC TAT TTC TGT     288
Leu Gln Met Ser Thr Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys
                205                 210                 215

GCG AGA GAT TCG GAA ACG GCA ATA GCG GCA GCT GGA CGG TTT GAT ATC     336
Ala Arg Asp Ser Glu Thr Ala Ile Ala Ala Ala Gly Arg Phe Asp Ile
            220                 225                 230

TGG GGC CAA GGG ACA ATG GTC ACC GTC TCT TCA                        369
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
        235                 240
```

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 123 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Gln Val Lys Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ser Asn Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Ser Thr Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys
85 90 95

Ala Arg Asp Ser Glu Thr Ala Ile Ala Ala Ala Gly Arg Phe Asp Ile
100 105 110

Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
115 120

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 366 base pairs
(B) TYPE: nucleotide
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA for mRNA

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:
(B) CLONE(E): AI-B18

(viii) POSITION IN THE GENOME:
(A) CHROMOSOME/SEGMENT: 14
(B) MAP POSITION: q32.3

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..366

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

```
CAG GTG AAA CTG CTC GAG TCT GGG GCT GAG GTG AAG AAG CCT GGG TCC        48
Gln Val Lys Leu Leu Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
    125                 130                 135

TCG GTG ATG GTC TCC TGC AAG GCT TCT GGA GGC ACC TTC AGC AGC CAT        96
Ser Val Met Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser His
140                 145                 150                 155

ACT ATC AGC TGG GTG CGG CAG GCC CCT GGA CAA GGC CTT GAG TGG ATG       144
Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                160                 165                 170

GGA GGG ATC ACC CCT ATC TTT GGT ACA GTG AAC TAC GCA CAG AAG TTC       192
Gly Gly Ile Thr Pro Ile Phe Gly Thr Val Asn Tyr Ala Gln Lys Phe
            175                 180                 185

CAG GGC AGA GTC ACC ATT ACC GCG GAC GAA CCC ACG AGC ACA GCC TAC       240
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Pro Thr Ser Thr Ala Tyr
        190                 195                 200

ATG GAA CTG AGG AGC CTG ACA TCT GAC GAC TCG GGC ATC TAT TAC TGT       288
Met Glu Leu Arg Ser Leu Thr Ser Asp Asp Ser Gly Ile Tyr Tyr Cys
    205                 210                 215

GCG AGA GAA GAT GGC ACT ACA GTA CCA AGT CAA CCC CTT GAG TTC TGG       336
Ala Arg Glu Asp Gly Thr Thr Val Pro Ser Gln Pro Leu Glu Phe Trp
220                 225                 230                 235

GGC CAG GGA ACC CGG GTC ACC GTC TCC TCT                               366
Gly Gln Gly Thr Arg Val Thr Val Ser Ser
                240                 245
```

(2) INFORMATION FOR SEQ ID NO: 24

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 122 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

```
Gln Val Lys Leu Leu Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15

Ser Val Met Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser His
            20                  25                  30

Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45

Gly Gly Ile Thr Pro Ile Phe Gly Thr Val Asn Tyr Ala Gln Lys Phe
    50                  55                  60

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Pro Thr Ser Thr Ala Tyr
65                  70                  75                  80

Met Glu Leu Arg Ser Leu Thr Ser Asp Asp Ser Gly Ile Tyr Tyr Cys
                85                  90                  95

Ala Arg Glu Asp Gly Thr Thr Val Pro Ser Gln Pro Leu Glu Phe Trp
            100                 105                 110

Gly Gln Gly Thr Arg Val Thr Val Ser Ser
        115                 120
```

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 363 base pairs
(B) TYPE: nucleotide
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA for mRNA

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:
(B) CLONE(E): AI-B24

(viii) POSITION IN THE GENOME:
(A) CHROMOSOME/SEGMENT: 14
(B) MAP POSITION: q32.3

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..363

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

```
CAG GTG AAA CTG CTC GAG TCT GGG GGA GGC TTG GTC CAG CCT GGG GGG      48
Gln Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
        125                 130                 135

TCC CTG AGA CTC TCC TGT TCA GCC TCT GGA TTC ACC TTC AAT AAA TAT      96
Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Asn Lys Tyr
    140                 145                 150

GCA ATA CAC TGG GTC CGC CAG GCT CCA GGG AAG GGA CTG GAA TAT GTT     144
Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val
155                 160                 165                 170

TCA GCT ATT AGT AGT AAT GGG GGT AAC ACA TAC TAC GCA GAC TCC GTG     192
Ser Ala Ile Ser Ser Asn Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val
                175                 180                 185

AAG GGC AGA TTC ACC ATC TCC AGA GAC AAT TCC AAG AAC ACG GTG TAT     240
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
            190                 195                 200

CTT CAA ATG AGC AGT CTG AGA GCT GAG GAC ACG GCT GTG TAT TAC TGT     288
Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
        205                 210                 215

GTT AGA GGA AGT GGG AGC TAC TTA GGA TAC TAC TTT GAC TAC TGG GGC     336
Val Arg Gly Ser Gly Ser Tyr Leu Gly Tyr Tyr Phe Asp Tyr Trp Gly
    220                 225                 230
```

CAG GGA ACC CTG GTC ACC GTC TCC TCA 363
Gln Gly Thr Leu Val Thr Val Ser Ser
235 240

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 121 base pairs
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

Gln Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Asn Lys Tyr
20 25 30

Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val
35 40 45

Ser Ala Ile Ser Ser Asn Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80

Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Val Arg Gly Ser Gly Ser Tyr Leu Gly Tyr Tyr Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 366 base pairs
(B) TYPE: nucleotide
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA for mRNA

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE(E): AI-B24

(viii) POSITION IN THE GENOME:

(A) CHROMOSOME/SEGMENT: 22

(B) MAP POSITION: q11

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..366

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

```
GTG GTG ACT CAG CCA CCC TCG GTG TCA GTG GCT CCA AGA CAG ACG GCC      48
Val Val Thr Gln Pro Pro Ser Val Ser Val Ala Pro Arg Gln Thr Ala
            125                 130                 135

ACG ATT ACC TGT GGG GGA TAC AAG ATT GGA AGT AAA AGT GTC CAC TGG      96
Thr Ile Thr Cys Gly Gly Tyr Lys Ile Gly Ser Lys Ser Val His Trp
        140                 145                 150

TAC CAA CAG AAG CCA GGC CAG GCC CCT GTA TTG GTC GTC TAT GAG GAT     144
Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Glu Asp
    155                 160                 165

TCC TAC CGG CCC TCA GAG ATC CCT GAG CGA TTC TCT GGC TCC AAC TCT     192
Ser Tyr Arg Pro Ser Glu Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser
170                 175                 180                 185

GGG AAC ATG GCC ACC CTG ACC ATC ACC GGG GTC GAA GCC GGG GAT GAG     240
Gly Asn Met Ala Thr Leu Thr Ile Thr Gly Val Glu Ala Gly Asp Glu
                190                 195                 200

GCC GAC TAC TAC TGT CAG GTG TGG GAT AAT ACT AAT GAT CAG ACG ATA     288
Ala Asp Tyr Tyr Cys Gln Val Trp Asp Asn Thr Asn Asp Gln Thr Ile
            205                 210                 215

TTC GGC GGA GGG ACC AAG CTG ACC GTC CTA CGT CAG CCC AAG GCT GCC     336
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Arg Gln Pro Lys Ala Ala
        220                 225                 230

CCC TCG GTC ACT CTG TTC CCG CCC TCC TCT                             366
Pro Ser Val Thr Leu Phe Pro Pro Ser Ser
    235                 240
```

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 122 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

Val Val Thr Gln Pro Pro Ser Val Ser Val Ala Pro Arg Gln Thr Ala
1 5 10 15

Thr Ile Thr Cys Gly Gly Tyr Lys Ile Gly Ser Lys Ser Val His Trp
20 25 30

Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Glu Asp
35 40 45

Ser Tyr Arg Pro Ser Glu Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser
50 55 60

Gly Asn Met Ala Thr Leu Thr Ile Thr Gly Val Glu Ala Gly Asp Glu
65 70 75 80

Ala Asp Tyr Tyr Cys Gln Val Trp Asp Asn Thr Asn Asp Gln Thr Ile
85 90 95

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Arg Gln Pro Lys Ala Ala
100 105 110

Pro Ser Val Thr Leu Phe Pro Pro Ser Ser
115 120

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 366 base pairs
(B) TYPE: nucleotide
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA for mRNA

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:
(B) CLONE(E): AI-B38

(viii) POSITION IN THE GENOME:
(A) CHROMOSOME/SEGMENT: 14
(B) MAP POSITION: q32.3

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..366

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

```
CAG GTG AAA CTG CTC GAG TCT GGG GCT GAG GTG AAG AAG CCT GGG GCC        48
Gln Val Lys Leu Leu Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
        125                 130                 135

TCA GTG AAG GTC TCC TGC AAG GTT TCC GGA TAC ACC CTC ACT GAA TTA        96
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
    140                 145                 150

TCC ATG CAC TGG GTG CGA CAG GCT CCT GGA AAA GGG CTT GAG TGG ATG       144
Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
155                 160                 165                 170

GGA GGT TTT GAT CCT GAA GAT GGT GAA ACA ATC TAC GCA CAG AAA TTC       192
Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
                175                 180                 185

CAG GGC AGA GTC ACC ATG ACC GAG GAC ACA TCT ACA GAC ACG GCC TAC       240
Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
            190                 195                 200

ATG GAG CTG AGC AGC CTG AGA TCT GAG GAC ACG GCC GTG TAT TAC TGT       288
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
        205                 210                 215

GAG ACA GGT CTG AGG TCG TAC AAC TAT GGT CGT AAC CTT GAC TAT TGG       336
Glu Thr Gly Leu Arg Ser Tyr Asn Tyr Gly Arg Asn Leu Asp Tyr Trp
    220                 225                 230

GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA                              366
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
235                 240
```

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 122 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

```
Gln Val Lys Leu Leu Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15

Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
            20                  25                  30

Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
        35                  40                  45

Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
    50                  55                  60

Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65                  70                  75                  80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95

Glu Thr Gly Leu Arg Ser Tyr Asn Tyr Gly Arg Asn Leu Asp Tyr Trp
            100                 105                 110
```

Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

Claims

1. Nucleic acid which encodes the heavy chain of a human antibody, or a functional derivative or a fragment thereof, and comprises a CDR3 region, selected from:
   (a) a nucleotide sequence which encodes the amino acid sequence:
   V L P F D P I S M D V, (I)
   (b) a nucleotide sequence which encodes the amino acid sequence:
   A L G S W G G W D H Y M D V, (II)
   (c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% with an amino acid sequence from (a) or (b), and
   (d) a nucleotide sequence which encodes an amino acid sequence having an equivalent ability to bind to GPIIb/IIIa.

2. Nucleic acid according to Claim 1, which furthermore comprises a CDR1 region selected from:
   (a) a nucleotide sequence which encodes the amino acid sequence:
   G Y S W R, (III)
   (b) a nucleotide sequence which encodes the amino acid sequence:
   S Y A M H, (IV)
   and
   (c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% with an amino acid sequence from (a) or (b).

3. Nucleic acid according to either Claim 1 or 2, which furthermore comprises a CDR2 region, selected from

(a) a nucleotide sequence which encodes the amino acid sequence:

D I S Y S G S T K Y K P S L R S, (V)

(b) a nucleotide sequence which encodes the amino acid sequence:

V I S Y D G S N K Y Y A D S V K G, (VI)

and

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% with an amino acid sequence from (a) or (b).

4. Nucleic acid which encodes the light chain of a human antibody, or a functional derivative or a fragment thereof, and comprises a CDR 3 region, selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:

A T W D D G L N G P V, (VII)

(b) a nucleotide sequence which encodes the amino acid sequence:

A A W D D S L N G W V, (VIII)

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% with an amino acid sequence from (a) or (b), and

(d) a nucleotide sequence which encodes an amino acid sequence having an equivalent ability to bind to GPIIb/IIIa.

5. Nucleic acid according to Claim 4, which furthermore comprises a CDR1 region selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:

S G S S S N I R S N P V S, (IX)

(b) a nucleotide sequence which encodes the amino acid sequence:

S G S S S N I G S N T V N, (X)

and

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% with an amino acid sequence from (a) or (b).

6. Nucleic acid according to Claim 4 or 5, which furthermore comprises a CDR2 region selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:

G S H Q R P S, (XI)

(b) a nucleotide sequence which encodes the amino acid sequence:

S N N Q R P S, (XII)

and

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% with an amino acid sequence from (a) or (b).

7. Nucleic acid which encodes the heavy chain of a human antibody, or a functional derivative or a fragment thereof, and comprises a CDR3 region, selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:

V R D L G Y R V L S T F T F D I, (XIII)

(b) a nucleotide sequence which encodes the amino acid sequence:

D G R S G S Y A R F D G M D V, (XIV)

(c) a nucleotide sequence which encodes the amino acid sequence:

M G S S V V A T Y N A F D I, (XV)

(d) a nucleotide sequence which encodes the amino acid sequence:

D A D G D G F S P Y Y F P Y, (XVI)

(e) a nucleotide sequence which encodes the amino acid sequence:

L R N D G W N D G F D I, (XVII)

(f) a nucleotide sequence which encodes the amino acid sequence:

D S E T A I A A A G R F D I, (XVIII)

(g) a nucleotide sequence which encodes the amino acid sequence:

E D G T T V P S Q P L E F, (XIX)

(h) a nucleotide sequence which encodes the amino acid sequence:

G S G S Y L G Y Y F D Y, (XX)

(i) a nucleotide sequence which encodes the amino acid sequence:

G L R S Y N Y G R N L D Y, (XXI)

(j) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% and preferably of at least 90%, with an amino acid sequence from (a), (b), (c) or (d), and

(k) a nucleotide sequence which encodes an amino acid sequence having an equivalent ability to bind to autoantibodies against GPIIb/IIIa.

8. Nucleic acid according to Claim 7, which furthermore comprises a CDR1 and/or CDR2 region selected from a nucleotide sequence which encodes the amino acid sequences shown in Tab. 7a or b or an amino acid sequence which is at least 80% homologous thereto.

9. Nucleic acid which encodes the light chain of a human antibody, or a functional derivative or a fragment thereof, and comprises a CDR 3 region, selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:

C S Y V H S S T N, (XXII)

(b) a nucleotide sequence which encodes the amino acid sequence:

Q V W D N T N D Q, (XXIII)

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80%, and preferably at least 90%, with an amino acid sequence from (a), and

(d) a nucleotide sequence which encodes an amino acid sequence having an equivalent ability to bind to autoantibodies against GPIIb/IIIa.

10. Nucleic acid from Claim 9, which furthermore encompasses a CDR1 and/or CDR2 region selected from a nucleotide sequence which encodes the amino acid sequences shown in Tab. 7a or b or an amino acid sequence which is at least 80% homologous thereto.

11. Vector, characterized in that it

(a) contains at least one copy of a nucleic acid according to one of Claims 1 to 3 and/or at least one copy of a nucleic acid according to one of Claims 4 to 6 or

(b) contains at least one copy of a nucleic acid according to Claim 7 or 8 and/or at least one copy of a nucleic acid according to Claim 9 or 10.

12. Cell, characterized in that it

(a) expresses a nucleic acid according to one of Claims 1 to 3 and/or a nucleic acid according to one of Claims 4 to 6 or

(b) a nucleic acid according to Claim 7 or 8 and/or a nucleic acid according to Claim 9 or 10.

13. Polypeptide, characterized in that it

(a) is encoded by a nucleic acid according to one of Claims 1 to 3 and/or a nucleic acid according to one of Claims 4 to 8 or

(b) by a nucleic acid according to Claim 7 or 8 and/or a nucleic acid according to Claim 9 or 10.

14. Polypeptide according to Claim 13, characterized in that it comprises the variable domain of the H chain and/or the variable domain of the L chain of a human antibody.

15. Polypeptide according to Claim 14, characterized in that it comprises both the variable domain of the H chain and the variable domain of the L chain.

16. Polypeptide according to one of Claims 13 to 15, characterized in that it is coupled to a labelling group or a toxin.

17. Antibody against a polypeptide according to one of Claims 13 to 16.

18. Antibody according to Claim 17, characterized in that it is directed against the CDR3 region of the heavy and/or light antibody chain of the polypeptide.

19. Pharmaceutical composition which comprises, as the active component, a nucleic acid according to one of Claims 1 to 10, a vector according to Claim 11, a cell according to Claim 12, a polypeptide according to one of Claims 13 to 16 or an antibody according to either Claim 17 or 18, where appropriate together with other active components and pharmaceutically customary adjuvants, additives or excipients.

20. Use of a nucleic acid according to one of Claims 1 to 10, of a vector according to Claim 11, of a cell according to Claim 12, of a polypeptide according to one of Claims 13 to 16, of an antibody according to Claim 17 or 18, or of a pharmaceutical composition according to Claim 19 for preparing an agent for the diagnosis or for the treatment or prevention of AITP.

21. Use of a nucleic acid according to one of Claims 1 to 10, of a vector according to Claim 11, of a cell according to Claim 12, of a polypeptide according to one of Claims 13 to 16, or of a pharmaceutical composition according to Claim 19 for preparing an agent for exerting an effect on the binding of fibrinogen to blood platelets.

22. Use according to Claim 21 for preparing an agent for modulating blood coagulation, in particular for dissolving thrombi and/or for preventing the formation of thrombi.

23. Process for isolating phagemid clones which express nucleic acids which encode autoantibodies against GPIIb/IIIa or encode antiidiotypic antibodies which are directed against these autoantibodies, characterized in that a phagemid library is prepared from lymphocytes obtained from a human donor and the desired phagemid clones are isolated by affinity selection, comprising negative and positive selection steps.

24. Process according to Claim 23, characterized in that antibody-encoding nucleic acids are isolated from the clones.

25. Process according to Claim 23 or 24, characterized in that the antibody-encoding nucleic acids are used for expressing recombinant antibody chains, or derivatives or fragments thereof.

Abstract

The invention relates to novel nucleic acid sequences which encode human autoantibodies and antiidiotypic antibodies against blood platelet membrane proteins, to novel amino acid sequences of human antibodies, and to their use for the diagnosis and therapy of diseases.

vo 05.06.98 13:49


PDG-X 660µg
PDG-X 220µg
100
75
50
25
0
Inhibition of the binding (in %)
0.05
0.5
5
50
Concentration of GPIIb/IIIa [µg]

Fig. 1


Fluorescence
(Mean value ± SD)
50
25
0
No phage
B30
B4
B14
B17
B18
B24
B38
Helper phage
Phage clones

Fig. 2



1 untreated blood platelets
2 EDTA-treated blood platelets

Fig.3

Fig 4




PDG-B binding, 7E3
PDG-B binding, ReoPro
PDG-A binding, 7E3
PDG-A binding, ReoPro
250
200
150
100
50
0
0,01
0,1
1
10
100
Concentration of the inhibitor [µg/ml]
Binding of PDG-B and PDG-A
(mean fluorescence intensity)

Fig. 5

Binding of PDG-B [2.6 µg/ml] to platelets
(mean fluorescence intensity)
80
70
60
50
40
30
20
10
0
0,0001
0,001
0,01
0,1
1
10
100
1000
Concentration of ReoPro® [µg/ml]
5 min incubation with PDG-B, then addition of ReoPro® for 1.5 h
Incubation with ReoPro® for 5 min, then addition of PDG for 1.5 h
Incubation with PDG-B and ReoPro, added simultaneously

Fig. 6



Fig. 7

N, M, M & O Docket No. _____ NIKAIDO, MARMELSTEIN, MURRAY & ORAM

Declaration For U.S. Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled (Insert Title) _____

the specification of which

(Check one of blocks 1, 2 or 3. See note A on back of this page)

1. ☐ is attached hereto.
2. ☒ was filed on June 05, 1998 as International PCT Application Serial No. PCT/EP 98/03397 and was amended on _____ (if applicable)
3. ☐ was filed on _____ as U.S. Application Serial No. _____ and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application for which priority is claimed:

(List prior foreign applications. See note B on back of this page)	(Number)	(Country)	(Day/Month/Year Filed)	Priority Claimed
	197 23 904.8	DE	June 06, 1997	☒ Yes ☐ No
	197 55 227.7	DE	December 12, 1997	☒ Yes ☐ No
	198 20 663.1	DE	May 08, 1998	☒ Yes ☐ No
				☐ Yes ☐ No

(See Note C on back of this page) ☐ See attached list for additional prior foreign applications

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT International filing date of this application:

(List prior U.S. Applications or PCT International applications designating the U.S.)	(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

And I hereby appoint as principal attorneys David T. Nikaido, Reg. No. 22,663; Charles M. Marmelstein, Reg. No. 25,895; George E. Oram, Jr., Reg. No. 27,931; Robert B. Murray, Reg. No. 22,980; Martin S. Postman, Reg. No. 18,570; E. Marcie Emas, Reg. No. 32,131; Michael G. Gilman, Reg. No. 19,114, Douglas H. Goldhush, Reg. No. 33,125; Kevin C. Brown, Reg. No. 32,402; Monica Chin Kins, Reg. No. 36,105; Sharon N. Klesner, Reg. No. 36,335, and John R. Fuisz, Reg. No. 37,327.

Please direct all communications to the following address: NIKAIDO, MARMELSTEIN, MURRAY & ORAM
Metropolitan Square
655 Fifteenth Street, N.W., Suite 330 - G Street Lobby
Washington, D.C. 20005-5701
(202) 638-5000 Fax: (202) 638-4810

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(See Note D on back of this page)

Full name of sole or first inventor: Peter Berchtold

Inventor's signature: P. Berchtold Date: 23.11.99

Residence: Waidweg 88, 3032 Hinterkappeln, SCHWEIZ

Citizenship: swiss CH

Post Office Address: same as above

Full name of second joint inventor, if any Robert F. A. Escher

Inventor's signature _____ Date 23.11.99

Residence Lentulusstraße 59, 3007 Bern, SCHWEIZ

Citizenship Swiss

Post Office Address same as above

Full name of third joint inventor, if any _____

Inventor's signature _____ Date

Residence _____

Citizenship _____

Post Office Address _____

Full name of fourth joint inventor, if any _____

Inventor's signature _____ Date

Residence _____

Citizenship _____

Post Office Address _____

Full name of fifth joint inventor, if any _____

Inventor's signature _____ Date

Residence _____

Citizenship _____

Post Office Address _____

Full name of sixth joint inventor, if any _____

Inventor's signature _____ Date

Residence _____

Citizenship _____

Post Office Address _____

Full name of seventh joint inventor, if any _____

Inventor's signature _____ Date

Residence _____

Citizenship _____

Post Office Address _____

Full name of eighth joint inventor, if any _____

Inventor's signature _____ Date

Residence _____

Citizenship _____

Post Office Address _____